This pipeline computes the correlation between significant arm-level copy number variations (cnvs) and selected clinical features.
Testing the association between copy number variation 82 arm-level events and 9 clinical features across 1085 patients, 363 significant findings detected with Q value < 0.25.
-
1p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
1q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
2p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
2q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
3p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
3q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
4p gain cnv correlated to 'Time to Death', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
4q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
5p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
5q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
6p gain cnv correlated to 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
6q gain cnv correlated to 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
7p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
7q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
8q gain cnv correlated to 'YEARS_TO_BIRTH'.
-
9p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', and 'HISTOLOGICAL_TYPE'.
-
9q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
10p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
10q gain cnv correlated to 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
11p gain cnv correlated to 'Time to Death', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
11q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
12p gain cnv correlated to 'TUMOR_TISSUE_SITE' and 'RADIATION_THERAPY'.
-
12q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
13q gain cnv correlated to 'YEARS_TO_BIRTH', 'RADIATION_THERAPY', and 'KARNOFSKY_PERFORMANCE_SCORE'.
-
14q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
15q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'KARNOFSKY_PERFORMANCE_SCORE'.
-
16p gain cnv correlated to 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
16q gain cnv correlated to 'TUMOR_TISSUE_SITE' and 'HISTOLOGICAL_TYPE'.
-
17p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', and 'HISTOLOGICAL_TYPE'.
-
17q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', and 'HISTOLOGICAL_TYPE'.
-
18p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
18q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
19p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
19q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
20p gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
20q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
21q gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
22q gain cnv correlated to 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
xp gain cnv correlated to 'Time to Death'.
-
xq gain cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
1p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
1q loss cnv correlated to 'Time to Death', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
2p loss cnv correlated to 'YEARS_TO_BIRTH'.
-
2q loss cnv correlated to 'TUMOR_TISSUE_SITE' and 'HISTOLOGICAL_TYPE'.
-
3p loss cnv correlated to 'RADIATION_THERAPY' and 'KARNOFSKY_PERFORMANCE_SCORE'.
-
3q loss cnv correlated to 'RADIATION_THERAPY'.
-
4p loss cnv correlated to 'Time to Death', 'TUMOR_TISSUE_SITE', 'GENDER', and 'HISTOLOGICAL_TYPE'.
-
4q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
5p loss cnv correlated to 'RADIATION_THERAPY' and 'HISTOLOGICAL_TYPE'.
-
5q loss cnv correlated to 'RADIATION_THERAPY' and 'HISTOLOGICAL_TYPE'.
-
6p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
6q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
7q loss cnv correlated to 'YEARS_TO_BIRTH'.
-
8p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
8q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
9p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
9q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'RACE'.
-
10p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'GENDER', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
10q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
11p loss cnv correlated to 'TUMOR_TISSUE_SITE', 'GENDER', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
11q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
12p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
12q loss cnv correlated to 'HISTOLOGICAL_TYPE' and 'RACE'.
-
13q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
14q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', 'RACE', and 'ETHNICITY'.
-
15q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
16p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', and 'HISTOLOGICAL_TYPE'.
-
16q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
17p loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
17q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
18p loss cnv correlated to 'YEARS_TO_BIRTH'.
-
19p loss cnv correlated to 'KARNOFSKY_PERFORMANCE_SCORE'.
-
19q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', 'HISTOLOGICAL_TYPE', and 'ETHNICITY'.
-
20p loss cnv correlated to 'TUMOR_TISSUE_SITE', 'GENDER', and 'RACE'.
-
20q loss cnv correlated to 'TUMOR_TISSUE_SITE', 'GENDER', and 'HISTOLOGICAL_TYPE'.
-
21q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
22q loss cnv correlated to 'Time to Death', 'YEARS_TO_BIRTH', 'TUMOR_TISSUE_SITE', 'RADIATION_THERAPY', 'KARNOFSKY_PERFORMANCE_SCORE', and 'HISTOLOGICAL_TYPE'.
-
xp loss cnv correlated to 'ETHNICITY'.
-
xq loss cnv correlated to 'Time to Death', 'TUMOR_TISSUE_SITE', and 'KARNOFSKY_PERFORMANCE_SCORE'.
Clinical Features |
Time to Death |
YEARS TO BIRTH |
TUMOR TISSUE SITE |
GENDER |
RADIATION THERAPY |
KARNOFSKY PERFORMANCE SCORE |
HISTOLOGICAL TYPE |
RACE | ETHNICITY | ||
nCNV (%) | nWild-Type | logrank test | Wilcoxon-test | Fisher's exact test | Fisher's exact test | Fisher's exact test | Wilcoxon-test | Fisher's exact test | Fisher's exact test | Fisher's exact test | |
10p loss | 559 (52%) | 526 |
0 (0) |
2.02e-74 (1.14e-72) |
1.94e-116 (1.43e-114) |
0.0846 (0.188) |
1.23e-15 (2.93e-14) |
2.7e-19 (7.65e-18) |
1e-05 (6.9e-05) |
0.00228 (0.00887) |
0.00298 (0.0113) |
7p gain | 591 (54%) | 494 |
0 (0) |
3.29e-55 (1.52e-53) |
4.91e-84 (3.02e-82) |
0.665 (0.791) |
1.24e-11 (2.24e-10) |
2.45e-13 (5.17e-12) |
1e-05 (6.9e-05) |
0.00203 (0.00801) |
0.0299 (0.0821) |
7q gain | 627 (58%) | 458 |
0 (0) |
1.25e-52 (5.45e-51) |
2.1e-71 (1.11e-69) |
0.35 (0.531) |
1.78e-10 (3.06e-09) |
1.53e-12 (2.89e-11) |
1e-05 (6.9e-05) |
0.00133 (0.00555) |
0.00749 (0.0248) |
20p gain | 265 (24%) | 820 |
0 (0) |
4.89e-28 (1.57e-26) |
1.82e-32 (6.39e-31) |
0.667 (0.792) |
2.51e-05 (0.000158) |
2.08e-05 (0.000132) |
1e-05 (6.9e-05) |
0.0859 (0.19) |
0.106 (0.222) |
20q gain | 262 (24%) | 823 |
0 (0) |
1.01e-26 (3.12e-25) |
2.26e-32 (7.58e-31) |
0.429 (0.601) |
1.61e-05 (0.000107) |
6.72e-06 (6.28e-05) |
1e-05 (6.9e-05) |
0.0777 (0.177) |
0.106 (0.222) |
21q gain | 88 (8%) | 997 |
0.00316 (0.0119) |
9.77e-07 (1.16e-05) |
8.45e-05 (0.000455) |
0.822 (0.908) |
0.0177 (0.0527) |
0.109 (0.228) |
0.00082 (0.00358) |
0.096 (0.205) |
0.0446 (0.115) |
6q loss | 188 (17%) | 897 |
1.41e-08 (2.03e-07) |
0.000709 (0.00315) |
3.86e-05 (0.000234) |
0.224 (0.394) |
0.0686 (0.162) |
0.00389 (0.0142) |
2e-05 (0.000128) |
0.0176 (0.0527) |
0.0954 (0.205) |
9p loss | 316 (29%) | 769 |
5.34e-06 (5.12e-05) |
9.23e-05 (0.00049) |
9.65e-06 (6.9e-05) |
1 (1.00) |
0.000449 (0.00206) |
0.0355 (0.0957) |
6e-05 (0.000341) |
0.119 (0.244) |
0.0603 (0.145) |
10q loss | 587 (54%) | 498 |
0 (0) |
2.15e-68 (1.06e-66) |
9.59e-116 (6.43e-114) |
0.175 (0.323) |
1.4e-18 (3.69e-17) |
6.88e-21 (2.03e-19) |
1e-05 (6.9e-05) |
0.004 (0.0145) |
0.000617 (0.00278) |
9q gain | 95 (9%) | 990 |
0.00943 (0.0304) |
0.00733 (0.0244) |
7.65e-06 (6.88e-05) |
0.0163 (0.0494) |
0.0564 (0.138) |
0.111 (0.231) |
6e-05 (0.000341) |
0.618 (0.756) |
0.784 (0.876) |
12q gain | 65 (6%) | 1020 |
0.00123 (0.0052) |
0.0694 (0.163) |
0.000165 (0.000835) |
1 (1.00) |
0.00943 (0.0304) |
0.0739 (0.17) |
0.00525 (0.0184) |
0.118 (0.243) |
0.168 (0.313) |
19q gain | 222 (20%) | 863 |
0 (0) |
5.33e-16 (1.31e-14) |
7.04e-35 (2.6e-33) |
0.594 (0.735) |
2.74e-06 (2.98e-05) |
5.35e-05 (0.000316) |
1e-05 (6.9e-05) |
0.0134 (0.0417) |
0.849 (0.918) |
xq gain | 57 (5%) | 1028 |
0.00236 (0.00912) |
0.000335 (0.00162) |
0.000358 (0.0017) |
0.0534 (0.133) |
0.623 (0.757) |
0.028 (0.0772) |
0.00019 (0.000954) |
0.716 (0.836) |
0.00399 (0.0145) |
1p loss | 200 (18%) | 885 |
0 (0) |
3.46e-05 (0.000213) |
4.74e-51 (1.95e-49) |
0.384 (0.565) |
1.16e-18 (3.16e-17) |
2.88e-06 (3.08e-05) |
1e-05 (6.9e-05) |
0.0844 (0.188) |
0.241 (0.417) |
9q loss | 141 (13%) | 944 |
0.00188 (0.00746) |
0.00228 (0.00887) |
0.00505 (0.0178) |
0.855 (0.92) |
0.000949 (0.00412) |
0.00123 (0.0052) |
0.0506 (0.127) |
0.0927 (0.199) |
0.257 (0.439) |
11q loss | 112 (10%) | 973 |
1.4e-09 (2.23e-08) |
8.94e-06 (6.9e-05) |
2.35e-10 (3.95e-09) |
0.686 (0.81) |
0.0187 (0.0549) |
0.033 (0.09) |
1e-05 (6.9e-05) |
1 (1.00) |
0.116 (0.239) |
14q loss | 226 (21%) | 859 |
5.44e-05 (0.000319) |
7.32e-05 (0.000409) |
0.000129 (0.000658) |
0.496 (0.655) |
0.29 (0.475) |
0.0403 (0.106) |
0.00109 (0.00465) |
0.0564 (0.138) |
0.0805 (0.181) |
19q loss | 244 (22%) | 841 |
0 (0) |
1.65e-08 (2.34e-07) |
2.55e-46 (9.91e-45) |
0.377 (0.561) |
1.16e-13 (2.6e-12) |
3.01e-06 (3.17e-05) |
1e-05 (6.9e-05) |
0.482 (0.642) |
0.00952 (0.0305) |
1p gain | 95 (9%) | 990 |
1.42e-09 (2.23e-08) |
1.61e-06 (1.88e-05) |
8.26e-13 (1.65e-11) |
0.514 (0.67) |
0.0783 (0.177) |
0.00102 (0.00438) |
1e-05 (6.9e-05) |
0.777 (0.871) |
0.571 (0.719) |
3q gain | 71 (7%) | 1014 |
1.1e-07 (1.45e-06) |
3.38e-07 (4.16e-06) |
4.75e-11 (8.35e-10) |
0.455 (0.629) |
0.0426 (0.112) |
0.0842 (0.188) |
1e-05 (6.9e-05) |
0.476 (0.636) |
0.513 (0.67) |
10p gain | 70 (6%) | 1015 |
2.05e-06 (2.32e-05) |
4.94e-12 (9.12e-11) |
1.58e-09 (2.43e-08) |
0.9 (0.953) |
0.297 (0.481) |
0.00406 (0.0146) |
1e-05 (6.9e-05) |
0.563 (0.712) |
0.0218 (0.0632) |
18q gain | 75 (7%) | 1010 |
2.6e-06 (2.9e-05) |
0.00142 (0.00584) |
2.03e-06 (2.32e-05) |
0.397 (0.573) |
0.0485 (0.123) |
0.022 (0.0635) |
2e-05 (0.000128) |
0.505 (0.663) |
0.357 (0.539) |
19p gain | 322 (30%) | 763 |
5.1e-06 (4.97e-05) |
3.12e-07 (3.9e-06) |
4.73e-13 (9.7e-12) |
0.501 (0.66) |
0.0585 (0.142) |
0.0229 (0.0656) |
1e-05 (6.9e-05) |
0.139 (0.276) |
0.313 (0.497) |
6p loss | 117 (11%) | 968 |
1.14e-12 (2.22e-11) |
0.000125 (0.000639) |
5.11e-06 (4.97e-05) |
0.692 (0.813) |
0.411 (0.585) |
0.0865 (0.19) |
8e-05 (0.000441) |
0.0437 (0.114) |
0.218 (0.389) |
8p loss | 75 (7%) | 1010 |
0.000115 (0.000598) |
0.000279 (0.00138) |
7.01e-06 (6.39e-05) |
0.397 (0.573) |
0.00613 (0.0209) |
0.457 (0.631) |
0.00031 (0.00152) |
0.00581 (0.02) |
0.762 (0.864) |
13q loss | 298 (27%) | 787 |
0.00152 (0.00618) |
0.0534 (0.133) |
0.000101 (0.000529) |
0.334 (0.519) |
0.0162 (0.0492) |
0.0959 (0.205) |
0.00337 (0.0126) |
0.536 (0.69) |
0.224 (0.394) |
22q loss | 240 (22%) | 845 |
2.15e-14 (4.97e-13) |
2.04e-13 (4.43e-12) |
4.56e-17 (1.16e-15) |
0.941 (0.985) |
0.00135 (0.00559) |
0.00647 (0.0219) |
1e-05 (6.9e-05) |
0.424 (0.598) |
0.195 (0.355) |
1q gain | 112 (10%) | 973 |
4.62e-05 (0.000277) |
2.63e-06 (2.9e-05) |
9.44e-10 (1.55e-08) |
0.312 (0.496) |
0.29 (0.475) |
0.00161 (0.00651) |
1e-05 (6.9e-05) |
0.404 (0.579) |
0.425 (0.599) |
2p gain | 51 (5%) | 1034 |
0.00562 (0.0196) |
0.026 (0.0727) |
0.00388 (0.0142) |
0.191 (0.349) |
0.394 (0.572) |
0.0893 (0.194) |
0.0701 (0.164) |
0.505 (0.663) |
0.716 (0.836) |
2q gain | 48 (4%) | 1037 |
0.00786 (0.0258) |
0.0158 (0.0483) |
0.00465 (0.0165) |
0.374 (0.56) |
0.16 (0.308) |
0.0587 (0.142) |
0.0728 (0.169) |
0.346 (0.531) |
1 (1.00) |
4q gain | 43 (4%) | 1042 |
0.00352 (0.0131) |
0.0157 (0.0482) |
0.000466 (0.00213) |
0.531 (0.686) |
0.0643 (0.154) |
0.746 (0.853) |
0.00358 (0.0133) |
0.287 (0.473) |
0.253 (0.436) |
9p gain | 64 (6%) | 1021 |
0.0254 (0.0721) |
0.0133 (0.0413) |
0.000694 (0.00311) |
0.0671 (0.159) |
0.128 (0.258) |
0.269 (0.449) |
0.00153 (0.0062) |
0.388 (0.568) |
0.734 (0.849) |
11q gain | 74 (7%) | 1011 |
1.79e-05 (0.000118) |
0.0123 (0.0387) |
4.43e-09 (6.67e-08) |
0.465 (0.633) |
0.163 (0.308) |
0.00725 (0.0242) |
1e-05 (6.9e-05) |
0.47 (0.636) |
0.223 (0.394) |
17p gain | 72 (7%) | 1013 |
2.65e-05 (0.000166) |
7.01e-06 (6.39e-05) |
0.00144 (0.00592) |
0.0261 (0.0727) |
1 (1.00) |
0.735 (0.849) |
0.00382 (0.0141) |
0.427 (0.599) |
0.762 (0.864) |
17q gain | 86 (8%) | 999 |
5.63e-07 (6.81e-06) |
6.2e-06 (5.87e-05) |
0.000445 (0.00206) |
0.087 (0.19) |
0.792 (0.884) |
0.647 (0.776) |
0.00571 (0.0198) |
0.719 (0.837) |
0.772 (0.869) |
18p gain | 78 (7%) | 1007 |
5.89e-05 (0.00034) |
0.0145 (0.0449) |
8.22e-05 (0.000446) |
0.634 (0.766) |
0.334 (0.519) |
0.0164 (0.0494) |
0.00074 (0.00325) |
0.662 (0.788) |
0.763 (0.864) |
4q loss | 149 (14%) | 936 |
9.07e-05 (0.000485) |
0.0177 (0.0527) |
6.59e-05 (0.000371) |
0.475 (0.636) |
0.046 (0.118) |
0.588 (0.732) |
8e-05 (0.000441) |
0.743 (0.852) |
0.651 (0.778) |
8q loss | 52 (5%) | 1033 |
4.28e-06 (4.33e-05) |
0.000324 (0.00157) |
9.33e-05 (0.000492) |
0.388 (0.568) |
0.016 (0.0489) |
0.799 (0.89) |
0.00489 (0.0173) |
0.151 (0.296) |
1 (1.00) |
16q loss | 104 (10%) | 981 |
5.86e-08 (7.87e-07) |
2.94e-05 (0.000182) |
1.23e-08 (1.81e-07) |
0.835 (0.913) |
0.0196 (0.0573) |
0.124 (0.251) |
1e-05 (6.9e-05) |
0.261 (0.441) |
1 (1.00) |
17p loss | 78 (7%) | 1007 |
7.82e-06 (6.9e-05) |
0.000118 (0.000611) |
2.98e-08 (4.07e-07) |
0.34 (0.526) |
0.161 (0.308) |
0.0027 (0.0104) |
1e-05 (6.9e-05) |
1 (1.00) |
0.548 (0.703) |
17q loss | 51 (5%) | 1034 |
1.11e-05 (7.61e-05) |
0.000383 (0.0018) |
9.74e-06 (6.9e-05) |
0.468 (0.635) |
0.392 (0.572) |
0.0277 (0.0765) |
0.00061 (0.00276) |
0.635 (0.766) |
0.454 (0.629) |
3p gain | 67 (6%) | 1018 |
1.42e-05 (9.63e-05) |
3.45e-06 (3.53e-05) |
1.79e-08 (2.49e-07) |
0.309 (0.494) |
0.295 (0.481) |
0.241 (0.417) |
1e-05 (6.9e-05) |
1 (1.00) |
0.509 (0.665) |
5p gain | 60 (6%) | 1025 |
4.69e-05 (0.000279) |
0.0115 (0.0364) |
3.35e-06 (3.48e-05) |
0.346 (0.531) |
0.348 (0.531) |
0.951 (0.993) |
2e-05 (0.000128) |
0.413 (0.586) |
1 (1.00) |
5q gain | 50 (5%) | 1035 |
3.51e-05 (0.000214) |
0.00124 (0.00522) |
1.61e-05 (0.000107) |
0.143 (0.284) |
0.865 (0.926) |
0.414 (0.586) |
0.0003 (0.00148) |
0.201 (0.364) |
0.26 (0.441) |
10q gain | 12 (1%) | 1073 |
0.842 (0.918) |
0.0527 (0.132) |
0.0781 (0.177) |
0.255 (0.439) |
0.309 (0.494) |
0.162 (0.308) |
0.0434 (0.113) |
0.171 (0.318) |
0.0861 (0.19) |
11p gain | 49 (5%) | 1036 |
0.0561 (0.138) |
0.704 (0.826) |
0.0122 (0.0383) |
0.462 (0.632) |
0.128 (0.258) |
0.12 (0.244) |
0.0184 (0.0543) |
0.378 (0.561) |
0.161 (0.308) |
14q gain | 26 (2%) | 1059 |
0.00183 (0.0073) |
0.00035 (0.00168) |
0.00105 (0.0045) |
0.316 (0.5) |
0.475 (0.636) |
0.185 (0.339) |
0.0066 (0.0222) |
1 (1.00) |
0.624 (0.757) |
15q gain | 37 (3%) | 1048 |
0.00596 (0.0204) |
0.064 (0.154) |
0.0926 (0.199) |
0.867 (0.926) |
0.847 (0.918) |
0.00771 (0.0254) |
0.237 (0.412) |
1 (1.00) |
0.394 (0.572) |
16p gain | 54 (5%) | 1031 |
0.589 (0.732) |
0.0572 (0.139) |
0.00793 (0.0259) |
0.257 (0.439) |
0.049 (0.123) |
0.363 (0.546) |
0.0411 (0.108) |
0.344 (0.531) |
0.162 (0.308) |
1q loss | 46 (4%) | 1039 |
0.0571 (0.139) |
0.463 (0.632) |
0.00616 (0.021) |
0.647 (0.776) |
0.0719 (0.167) |
0.522 (0.675) |
0.00024 (0.0012) |
0.816 (0.906) |
0.717 (0.836) |
4p loss | 127 (12%) | 958 |
0.0548 (0.136) |
0.884 (0.941) |
0.0378 (0.101) |
0.0355 (0.0957) |
0.261 (0.441) |
0.766 (0.865) |
0.00037 (0.00175) |
0.256 (0.439) |
0.473 (0.636) |
11p loss | 162 (15%) | 923 |
0.151 (0.295) |
0.847 (0.918) |
0.0404 (0.106) |
0.0246 (0.07) |
0.0115 (0.0364) |
0.651 (0.778) |
0.00042 (0.00196) |
0.588 (0.732) |
0.384 (0.565) |
12p loss | 84 (8%) | 1001 |
0.00662 (0.0222) |
0.0461 (0.118) |
0.00431 (0.0155) |
0.647 (0.776) |
0.347 (0.531) |
0.279 (0.461) |
0.0178 (0.0528) |
0.222 (0.393) |
0.571 (0.719) |
15q loss | 154 (14%) | 931 |
0.00288 (0.0109) |
5.8e-05 (0.000337) |
8.13e-05 (0.000444) |
0.93 (0.975) |
0.757 (0.862) |
0.187 (0.342) |
0.00275 (0.0105) |
0.916 (0.964) |
0.825 (0.908) |
16p loss | 78 (7%) | 1007 |
1.82e-07 (2.32e-06) |
4.4e-06 (4.39e-05) |
1.27e-07 (1.65e-06) |
0.407 (0.583) |
0.161 (0.308) |
0.427 (0.599) |
1e-05 (6.9e-05) |
0.885 (0.941) |
1 (1.00) |
4p gain | 48 (4%) | 1037 |
0.0376 (0.101) |
0.159 (0.308) |
0.00465 (0.0165) |
1 (1.00) |
0.162 (0.308) |
0.291 (0.476) |
0.0111 (0.0354) |
0.269 (0.449) |
0.717 (0.836) |
6p gain | 35 (3%) | 1050 |
0.303 (0.487) |
0.772 (0.869) |
0.0258 (0.0725) |
0.864 (0.926) |
0.0258 (0.0725) |
0.328 (0.515) |
0.098 (0.208) |
0.549 (0.703) |
0.634 (0.766) |
6q gain | 28 (3%) | 1057 |
0.277 (0.459) |
0.852 (0.919) |
0.0017 (0.00681) |
0.848 (0.918) |
0.114 (0.237) |
0.277 (0.459) |
0.0328 (0.0896) |
0.484 (0.644) |
0.619 (0.756) |
13q gain | 17 (2%) | 1068 |
0.263 (0.442) |
0.0741 (0.17) |
0.807 (0.899) |
0.458 (0.631) |
0.069 (0.162) |
0.021 (0.0611) |
0.832 (0.913) |
1 (1.00) |
1 (1.00) |
22q gain | 57 (5%) | 1028 |
0.275 (0.458) |
0.176 (0.324) |
0.496 (0.655) |
0.891 (0.944) |
0.522 (0.675) |
0.076 (0.173) |
0.00903 (0.0294) |
0.923 (0.97) |
0.0665 (0.158) |
20p loss | 26 (2%) | 1059 |
0.223 (0.394) |
0.765 (0.864) |
0.0456 (0.118) |
0.109 (0.228) |
0.166 (0.311) |
0.573 (0.719) |
0.26 (0.441) |
0.0664 (0.158) |
0.3 (0.485) |
20q loss | 21 (2%) | 1064 |
0.214 (0.383) |
0.381 (0.564) |
0.0132 (0.0413) |
0.0734 (0.169) |
0.62 (0.756) |
0.832 (0.913) |
0.076 (0.173) |
0.37 (0.554) |
0.592 (0.734) |
xq loss | 174 (16%) | 911 |
0.0895 (0.194) |
0.212 (0.382) |
0.047 (0.12) |
0.867 (0.926) |
0.376 (0.561) |
0.0881 (0.192) |
0.381 (0.564) |
0.451 (0.626) |
0.675 (0.8) |
12p gain | 93 (9%) | 992 |
0.226 (0.395) |
0.777 (0.871) |
0.0221 (0.0636) |
0.742 (0.852) |
0.000447 (0.00206) |
0.46 (0.632) |
0.14 (0.278) |
0.906 (0.957) |
0.572 (0.719) |
16q gain | 57 (5%) | 1028 |
0.339 (0.526) |
0.301 (0.486) |
0.0401 (0.106) |
0.409 (0.584) |
0.15 (0.295) |
0.475 (0.636) |
0.0189 (0.0552) |
0.435 (0.607) |
0.163 (0.308) |
2q loss | 52 (5%) | 1033 |
0.183 (0.336) |
0.198 (0.358) |
0.12 (0.244) |
0.388 (0.568) |
0.738 (0.851) |
0.359 (0.542) |
0.073 (0.169) |
0.642 (0.773) |
0.263 (0.442) |
3p loss | 70 (6%) | 1015 |
0.36 (0.543) |
0.351 (0.531) |
0.461 (0.632) |
0.618 (0.756) |
0.0272 (0.0755) |
0.0339 (0.0919) |
0.882 (0.94) |
0.82 (0.907) |
0.201 (0.363) |
5p loss | 80 (7%) | 1005 |
0.491 (0.651) |
0.997 (1.00) |
0.728 (0.845) |
1 (1.00) |
0.0021 (0.00825) |
0.242 (0.418) |
0.0472 (0.12) |
0.466 (0.633) |
0.764 (0.864) |
5q loss | 80 (7%) | 1005 |
0.847 (0.918) |
0.979 (1.00) |
0.416 (0.589) |
0.557 (0.709) |
0.00073 (0.00322) |
0.436 (0.607) |
0.0847 (0.188) |
0.841 (0.918) |
0.558 (0.709) |
12q loss | 108 (10%) | 977 |
0.951 (0.993) |
0.996 (1.00) |
0.686 (0.81) |
0.539 (0.693) |
0.81 (0.9) |
0.962 (1.00) |
0.0257 (0.0725) |
0.0486 (0.123) |
0.613 (0.752) |
8q gain | 117 (11%) | 968 |
0.256 (0.439) |
0.0974 (0.207) |
0.624 (0.757) |
0.692 (0.813) |
0.161 (0.308) |
0.863 (0.926) |
0.296 (0.481) |
0.583 (0.729) |
0.127 (0.257) |
xp gain | 35 (3%) | 1050 |
0.0866 (0.19) |
0.173 (0.32) |
0.302 (0.486) |
0.163 (0.308) |
0.226 (0.395) |
0.233 (0.406) |
0.164 (0.309) |
0.55 (0.703) |
0.317 (0.501) |
2p loss | 54 (5%) | 1031 |
0.165 (0.31) |
0.0661 (0.158) |
0.402 (0.577) |
0.326 (0.514) |
0.41 (0.585) |
0.351 (0.531) |
0.472 (0.636) |
0.601 (0.741) |
0.267 (0.447) |
3q loss | 62 (6%) | 1023 |
0.391 (0.571) |
0.994 (1.00) |
1 (1.00) |
1 (1.00) |
0.115 (0.239) |
0.4 (0.575) |
0.997 (1.00) |
0.479 (0.639) |
0.734 (0.849) |
7q loss | 9 (1%) | 1076 |
0.93 (0.975) |
0.0919 (0.199) |
1 (1.00) |
0.742 (0.852) |
0.687 (0.81) |
0.203 (0.365) |
0.747 (0.853) |
0.563 (0.712) |
1 (1.00) |
18p loss | 137 (13%) | 948 |
0.333 (0.519) |
0.101 (0.214) |
0.855 (0.92) |
0.139 (0.276) |
0.515 (0.671) |
0.488 (0.648) |
0.436 (0.607) |
0.219 (0.389) |
1 (1.00) |
19p loss | 57 (5%) | 1028 |
0.145 (0.285) |
0.159 (0.308) |
0.175 (0.323) |
0.891 (0.944) |
1 (1.00) |
0.102 (0.215) |
0.589 (0.732) |
0.394 (0.572) |
0.28 (0.462) |
21q loss | 78 (7%) | 1007 |
0.728 (0.845) |
0.334 (0.519) |
0.906 (0.957) |
0.34 (0.526) |
0.322 (0.508) |
0.835 (0.913) |
0.0358 (0.0962) |
0.743 (0.852) |
0.558 (0.709) |
xp loss | 211 (19%) | 874 |
0.823 (0.908) |
0.398 (0.574) |
0.818 (0.907) |
0.312 (0.496) |
0.521 (0.675) |
0.376 (0.561) |
0.969 (1.00) |
0.558 (0.709) |
0.119 (0.244) |
8p gain | 101 (9%) | 984 |
0.602 (0.741) |
0.661 (0.788) |
0.834 (0.913) |
0.916 (0.964) |
0.453 (0.629) |
0.581 (0.728) |
0.519 (0.674) |
0.217 (0.388) |
0.29 (0.475) |
7p loss | 10 (1%) | 1075 |
0.623 (0.757) |
0.135 (0.271) |
0.349 (0.531) |
0.75 (0.855) |
0.463 (0.632) |
0.844 (0.918) |
0.781 (0.875) |
0.607 (0.747) |
1 (1.00) |
18q loss | 123 (11%) | 962 |
0.13 (0.261) |
0.473 (0.636) |
0.502 (0.661) |
0.561 (0.711) |
0.306 (0.491) |
0.601 (0.741) |
0.146 (0.287) |
0.166 (0.311) |
0.334 (0.519) |
P value = 1.42e-09 (logrank test), Q value = 2.2e-08
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
1P GAIN MUTATED | 95 | 73 | 0.2 - 92.7 (12.6) |
1P GAIN WILD-TYPE | 983 | 525 | 0.0 - 211.2 (16.6) |
P value = 1.61e-06 (Wilcoxon-test), Q value = 1.9e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
1P GAIN MUTATED | 95 | 57.9 (13.9) |
1P GAIN WILD-TYPE | 989 | 50.1 (15.8) |
P value = 8.26e-13 (Fisher's exact test), Q value = 1.6e-11
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
1P GAIN MUTATED | 82 | 13 |
1P GAIN WILD-TYPE | 491 | 499 |
P value = 0.0783 (Fisher's exact test), Q value = 0.18
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
1P GAIN MUTATED | 16 | 76 |
1P GAIN WILD-TYPE | 242 | 694 |
P value = 0.00102 (Wilcoxon-test), Q value = 0.0044
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
1P GAIN MUTATED | 67 | 75.1 (17.2) |
1P GAIN WILD-TYPE | 665 | 81.7 (15.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
1P GAIN MUTATED | 10 | 1 | 0 | 3 | 1 | 80 |
1P GAIN WILD-TYPE | 184 | 29 | 129 | 186 | 17 | 445 |
P value = 4.62e-05 (logrank test), Q value = 0.00028
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
1Q GAIN MUTATED | 112 | 79 | 0.1 - 211.2 (13.6) |
1Q GAIN WILD-TYPE | 966 | 519 | 0.0 - 182.3 (16.5) |
P value = 2.63e-06 (Wilcoxon-test), Q value = 2.9e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
1Q GAIN MUTATED | 112 | 57.1 (15.1) |
1Q GAIN WILD-TYPE | 972 | 50.1 (15.7) |
P value = 9.44e-10 (Fisher's exact test), Q value = 1.5e-08
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
1Q GAIN MUTATED | 89 | 23 |
1Q GAIN WILD-TYPE | 484 | 489 |
P value = 0.00161 (Wilcoxon-test), Q value = 0.0065
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
1Q GAIN MUTATED | 76 | 75.9 (16.7) |
1Q GAIN WILD-TYPE | 656 | 81.7 (15.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
1Q GAIN MUTATED | 13 | 2 | 2 | 8 | 2 | 85 |
1Q GAIN WILD-TYPE | 181 | 28 | 127 | 181 | 16 | 440 |
P value = 0.00562 (logrank test), Q value = 0.02
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
2P GAIN MUTATED | 50 | 36 | 0.2 - 92.7 (14.3) |
2P GAIN WILD-TYPE | 1028 | 562 | 0.0 - 211.2 (16.2) |
P value = 0.026 (Wilcoxon-test), Q value = 0.073
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
2P GAIN MUTATED | 51 | 55.4 (16.2) |
2P GAIN WILD-TYPE | 1033 | 50.6 (15.8) |
P value = 0.00388 (Fisher's exact test), Q value = 0.014
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
2P GAIN MUTATED | 37 | 14 |
2P GAIN WILD-TYPE | 536 | 498 |
P value = 0.0893 (Wilcoxon-test), Q value = 0.19
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
2P GAIN MUTATED | 36 | 77.8 (13.3) |
2P GAIN WILD-TYPE | 696 | 81.2 (15.4) |
P value = 0.0701 (Fisher's exact test), Q value = 0.16
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
2P GAIN MUTATED | 7 | 1 | 2 | 5 | 1 | 35 |
2P GAIN WILD-TYPE | 187 | 29 | 127 | 184 | 17 | 490 |
P value = 0.00786 (logrank test), Q value = 0.026
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
2Q GAIN MUTATED | 47 | 33 | 0.2 - 92.7 (14.3) |
2Q GAIN WILD-TYPE | 1031 | 565 | 0.0 - 211.2 (16.2) |
P value = 0.0158 (Wilcoxon-test), Q value = 0.048
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
2Q GAIN MUTATED | 48 | 55.9 (16.2) |
2Q GAIN WILD-TYPE | 1036 | 50.6 (15.7) |
P value = 0.00465 (Fisher's exact test), Q value = 0.017
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
2Q GAIN MUTATED | 35 | 13 |
2Q GAIN WILD-TYPE | 538 | 499 |
P value = 0.0587 (Wilcoxon-test), Q value = 0.14
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
2Q GAIN MUTATED | 36 | 77.2 (13.7) |
2Q GAIN WILD-TYPE | 696 | 81.3 (15.4) |
P value = 0.0728 (Fisher's exact test), Q value = 0.17
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
2Q GAIN MUTATED | 7 | 1 | 2 | 4 | 1 | 33 |
2Q GAIN WILD-TYPE | 187 | 29 | 127 | 185 | 17 | 492 |
P value = 1.42e-05 (logrank test), Q value = 9.6e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
3P GAIN MUTATED | 67 | 51 | 0.2 - 127.6 (11.0) |
3P GAIN WILD-TYPE | 1011 | 547 | 0.0 - 211.2 (16.2) |
P value = 3.45e-06 (Wilcoxon-test), Q value = 3.5e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
3P GAIN MUTATED | 67 | 59.4 (13.8) |
3P GAIN WILD-TYPE | 1017 | 50.3 (15.8) |
P value = 1.79e-08 (Fisher's exact test), Q value = 2.5e-07
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
3P GAIN MUTATED | 57 | 10 |
3P GAIN WILD-TYPE | 516 | 502 |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
3P GAIN MUTATED | 7 | 1 | 0 | 3 | 1 | 55 |
3P GAIN WILD-TYPE | 187 | 29 | 129 | 186 | 17 | 470 |
P value = 1.1e-07 (logrank test), Q value = 1.4e-06
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
3Q GAIN MUTATED | 71 | 56 | 0.2 - 127.6 (10.6) |
3Q GAIN WILD-TYPE | 1007 | 542 | 0.0 - 211.2 (16.4) |
P value = 3.38e-07 (Wilcoxon-test), Q value = 4.2e-06
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
3Q GAIN MUTATED | 71 | 59.8 (13.6) |
3Q GAIN WILD-TYPE | 1013 | 50.2 (15.8) |
P value = 4.75e-11 (Fisher's exact test), Q value = 8.3e-10
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
3Q GAIN MUTATED | 63 | 8 |
3Q GAIN WILD-TYPE | 510 | 504 |
P value = 0.0426 (Fisher's exact test), Q value = 0.11
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
3Q GAIN MUTATED | 10 | 58 |
3Q GAIN WILD-TYPE | 248 | 712 |
P value = 0.0842 (Wilcoxon-test), Q value = 0.19
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
3Q GAIN MUTATED | 51 | 79.0 (12.0) |
3Q GAIN WILD-TYPE | 681 | 81.2 (15.5) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
3Q GAIN MUTATED | 6 | 1 | 0 | 2 | 1 | 61 |
3Q GAIN WILD-TYPE | 188 | 29 | 129 | 187 | 17 | 464 |
P value = 0.0376 (logrank test), Q value = 0.1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
4P GAIN MUTATED | 48 | 33 | 0.2 - 92.7 (13.4) |
4P GAIN WILD-TYPE | 1030 | 565 | 0.0 - 211.2 (16.0) |
P value = 0.00465 (Fisher's exact test), Q value = 0.017
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
4P GAIN MUTATED | 35 | 13 |
4P GAIN WILD-TYPE | 538 | 499 |
P value = 0.0111 (Fisher's exact test), Q value = 0.035
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
4P GAIN MUTATED | 8 | 1 | 0 | 5 | 1 | 33 |
4P GAIN WILD-TYPE | 186 | 29 | 129 | 184 | 17 | 492 |
P value = 0.00352 (logrank test), Q value = 0.013
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
4Q GAIN MUTATED | 43 | 31 | 0.2 - 92.7 (12.8) |
4Q GAIN WILD-TYPE | 1035 | 567 | 0.0 - 211.2 (16.1) |
P value = 0.0157 (Wilcoxon-test), Q value = 0.048
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
4Q GAIN MUTATED | 43 | 56.0 (15.8) |
4Q GAIN WILD-TYPE | 1041 | 50.6 (15.8) |
P value = 0.000466 (Fisher's exact test), Q value = 0.0021
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
4Q GAIN MUTATED | 34 | 9 |
4Q GAIN WILD-TYPE | 539 | 503 |
P value = 0.0643 (Fisher's exact test), Q value = 0.15
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
4Q GAIN MUTATED | 5 | 36 |
4Q GAIN WILD-TYPE | 253 | 734 |
P value = 0.00358 (Fisher's exact test), Q value = 0.013
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
4Q GAIN MUTATED | 6 | 1 | 0 | 3 | 1 | 32 |
4Q GAIN WILD-TYPE | 188 | 29 | 129 | 186 | 17 | 493 |
P value = 4.69e-05 (logrank test), Q value = 0.00028
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
5P GAIN MUTATED | 60 | 49 | 1.1 - 92.7 (12.4) |
5P GAIN WILD-TYPE | 1018 | 549 | 0.0 - 211.2 (16.2) |
P value = 0.0115 (Wilcoxon-test), Q value = 0.036
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
5P GAIN MUTATED | 60 | 55.7 (15.1) |
5P GAIN WILD-TYPE | 1024 | 50.5 (15.8) |
P value = 3.35e-06 (Fisher's exact test), Q value = 3.5e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
5P GAIN MUTATED | 49 | 11 |
5P GAIN WILD-TYPE | 524 | 501 |
P value = 2e-05 (Fisher's exact test), Q value = 0.00013
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
5P GAIN MUTATED | 7 | 3 | 2 | 2 | 4 | 42 |
5P GAIN WILD-TYPE | 187 | 27 | 127 | 187 | 14 | 483 |
P value = 3.51e-05 (logrank test), Q value = 0.00021
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
5Q GAIN MUTATED | 50 | 40 | 1.1 - 92.7 (9.1) |
5Q GAIN WILD-TYPE | 1028 | 558 | 0.0 - 211.2 (16.3) |
P value = 0.00124 (Wilcoxon-test), Q value = 0.0052
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
5Q GAIN MUTATED | 50 | 57.8 (13.8) |
5Q GAIN WILD-TYPE | 1034 | 50.5 (15.8) |
P value = 1.61e-05 (Fisher's exact test), Q value = 0.00011
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
5Q GAIN MUTATED | 41 | 9 |
5Q GAIN WILD-TYPE | 532 | 503 |
P value = 3e-04 (Fisher's exact test), Q value = 0.0015
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
5Q GAIN MUTATED | 5 | 3 | 2 | 2 | 3 | 35 |
5Q GAIN WILD-TYPE | 189 | 27 | 127 | 187 | 15 | 490 |
P value = 0.0258 (Fisher's exact test), Q value = 0.073
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
6P GAIN MUTATED | 25 | 10 |
6P GAIN WILD-TYPE | 548 | 502 |
P value = 0.0258 (Fisher's exact test), Q value = 0.073
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
6P GAIN MUTATED | 3 | 31 |
6P GAIN WILD-TYPE | 255 | 739 |
P value = 0.098 (Fisher's exact test), Q value = 0.21
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
6P GAIN MUTATED | 7 | 1 | 1 | 2 | 0 | 24 |
6P GAIN WILD-TYPE | 187 | 29 | 128 | 187 | 18 | 501 |
P value = 0.0017 (Fisher's exact test), Q value = 0.0068
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
6Q GAIN MUTATED | 23 | 5 |
6Q GAIN WILD-TYPE | 550 | 507 |
P value = 0.114 (Fisher's exact test), Q value = 0.24
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
6Q GAIN MUTATED | 3 | 24 |
6Q GAIN WILD-TYPE | 255 | 746 |
P value = 0.0328 (Fisher's exact test), Q value = 0.09
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
6Q GAIN MUTATED | 3 | 1 | 0 | 2 | 0 | 22 |
6Q GAIN WILD-TYPE | 191 | 29 | 129 | 187 | 18 | 503 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
7P GAIN MUTATED | 588 | 445 | 0.1 - 211.2 (13.0) |
7P GAIN WILD-TYPE | 490 | 153 | 0.0 - 182.3 (21.3) |
P value = 3.29e-55 (Wilcoxon-test), Q value = 1.5e-53
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
7P GAIN MUTATED | 591 | 57.6 (13.1) |
7P GAIN WILD-TYPE | 493 | 42.6 (14.9) |
P value = 4.91e-84 (Fisher's exact test), Q value = 3e-82
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
7P GAIN MUTATED | 467 | 124 |
7P GAIN WILD-TYPE | 106 | 388 |
P value = 1.24e-11 (Fisher's exact test), Q value = 2.2e-10
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
7P GAIN MUTATED | 93 | 466 |
7P GAIN WILD-TYPE | 165 | 304 |
P value = 2.45e-13 (Wilcoxon-test), Q value = 5.2e-12
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
7P GAIN MUTATED | 423 | 77.8 (16.1) |
7P GAIN WILD-TYPE | 309 | 85.6 (12.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
7P GAIN MUTATED | 52 | 22 | 31 | 41 | 12 | 433 |
7P GAIN WILD-TYPE | 142 | 8 | 98 | 148 | 6 | 92 |
P value = 0.00203 (Fisher's exact test), Q value = 0.008
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
7P GAIN MUTATED | 1 | 9 | 52 | 508 |
7P GAIN WILD-TYPE | 0 | 12 | 19 | 451 |
P value = 0.0299 (Fisher's exact test), Q value = 0.082
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
7P GAIN MUTATED | 16 | 494 |
7P GAIN WILD-TYPE | 28 | 427 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
7Q GAIN MUTATED | 624 | 456 | 0.1 - 211.2 (13.5) |
7Q GAIN WILD-TYPE | 454 | 142 | 0.0 - 182.3 (22.3) |
P value = 1.25e-52 (Wilcoxon-test), Q value = 5.4e-51
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
7Q GAIN MUTATED | 627 | 57.0 (13.2) |
7Q GAIN WILD-TYPE | 457 | 42.3 (15.0) |
P value = 2.1e-71 (Fisher's exact test), Q value = 1.1e-69
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
7Q GAIN MUTATED | 473 | 154 |
7Q GAIN WILD-TYPE | 100 | 358 |
P value = 1.78e-10 (Fisher's exact test), Q value = 3.1e-09
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
7Q GAIN MUTATED | 104 | 487 |
7Q GAIN WILD-TYPE | 154 | 283 |
P value = 1.53e-12 (Wilcoxon-test), Q value = 2.9e-11
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
7Q GAIN MUTATED | 440 | 78.0 (16.1) |
7Q GAIN WILD-TYPE | 292 | 85.7 (12.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
7Q GAIN MUTATED | 67 | 23 | 39 | 48 | 12 | 438 |
7Q GAIN WILD-TYPE | 127 | 7 | 90 | 141 | 6 | 87 |
P value = 0.00133 (Fisher's exact test), Q value = 0.0055
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
7Q GAIN MUTATED | 1 | 10 | 55 | 540 |
7Q GAIN WILD-TYPE | 0 | 11 | 16 | 419 |
P value = 0.00749 (Fisher's exact test), Q value = 0.025
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
7Q GAIN MUTATED | 16 | 531 |
7Q GAIN WILD-TYPE | 28 | 390 |
P value = 0.0974 (Wilcoxon-test), Q value = 0.21
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
8Q GAIN MUTATED | 117 | 48.3 (16.5) |
8Q GAIN WILD-TYPE | 967 | 51.1 (15.7) |
P value = 0.0254 (logrank test), Q value = 0.072
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
9P GAIN MUTATED | 64 | 44 | 0.4 - 172.8 (13.7) |
9P GAIN WILD-TYPE | 1014 | 554 | 0.0 - 211.2 (16.2) |
P value = 0.0133 (Wilcoxon-test), Q value = 0.041
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
9P GAIN MUTATED | 64 | 54.8 (16.9) |
9P GAIN WILD-TYPE | 1020 | 50.6 (15.7) |
P value = 0.000694 (Fisher's exact test), Q value = 0.0031
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
9P GAIN MUTATED | 47 | 17 |
9P GAIN WILD-TYPE | 526 | 495 |
P value = 0.0671 (Fisher's exact test), Q value = 0.16
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
9P GAIN MUTATED | 34 | 30 |
9P GAIN WILD-TYPE | 419 | 602 |
P value = 0.00153 (Fisher's exact test), Q value = 0.0062
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
9P GAIN MUTATED | 8 | 0 | 6 | 3 | 0 | 47 |
9P GAIN WILD-TYPE | 186 | 30 | 123 | 186 | 18 | 478 |
P value = 0.00943 (logrank test), Q value = 0.03
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
9Q GAIN MUTATED | 95 | 68 | 0.4 - 172.8 (15.0) |
9Q GAIN WILD-TYPE | 983 | 530 | 0.0 - 211.2 (16.1) |
P value = 0.00733 (Wilcoxon-test), Q value = 0.024
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
9Q GAIN MUTATED | 95 | 54.6 (15.7) |
9Q GAIN WILD-TYPE | 989 | 50.4 (15.8) |
P value = 7.65e-06 (Fisher's exact test), Q value = 6.9e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
9Q GAIN MUTATED | 71 | 24 |
9Q GAIN WILD-TYPE | 502 | 488 |
P value = 0.0163 (Fisher's exact test), Q value = 0.049
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
9Q GAIN MUTATED | 51 | 44 |
9Q GAIN WILD-TYPE | 402 | 588 |
P value = 0.0564 (Fisher's exact test), Q value = 0.14
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
9Q GAIN MUTATED | 15 | 75 |
9Q GAIN WILD-TYPE | 243 | 695 |
P value = 0.111 (Wilcoxon-test), Q value = 0.23
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
9Q GAIN MUTATED | 73 | 78.1 (17.4) |
9Q GAIN WILD-TYPE | 659 | 81.4 (15.0) |
P value = 6e-05 (Fisher's exact test), Q value = 0.00034
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
9Q GAIN MUTATED | 13 | 2 | 7 | 4 | 2 | 67 |
9Q GAIN WILD-TYPE | 181 | 28 | 122 | 185 | 16 | 458 |
P value = 2.05e-06 (logrank test), Q value = 2.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
10P GAIN MUTATED | 70 | 21 | 0.1 - 172.8 (27.4) |
10P GAIN WILD-TYPE | 1008 | 577 | 0.0 - 211.2 (15.4) |
P value = 4.94e-12 (Wilcoxon-test), Q value = 9.1e-11
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
10P GAIN MUTATED | 70 | 38.3 (12.2) |
10P GAIN WILD-TYPE | 1014 | 51.7 (15.7) |
P value = 1.58e-09 (Fisher's exact test), Q value = 2.4e-08
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
10P GAIN MUTATED | 13 | 57 |
10P GAIN WILD-TYPE | 560 | 455 |
P value = 0.00406 (Wilcoxon-test), Q value = 0.015
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
10P GAIN MUTATED | 44 | 87.0 (10.7) |
10P GAIN WILD-TYPE | 688 | 80.7 (15.5) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
10P GAIN MUTATED | 32 | 1 | 17 | 8 | 1 | 11 |
10P GAIN WILD-TYPE | 162 | 29 | 112 | 181 | 17 | 514 |
P value = 0.0218 (Fisher's exact test), Q value = 0.063
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
10P GAIN MUTATED | 7 | 57 |
10P GAIN WILD-TYPE | 37 | 864 |
P value = 0.0527 (Wilcoxon-test), Q value = 0.13
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
10Q GAIN MUTATED | 12 | 42.1 (17.6) |
10Q GAIN WILD-TYPE | 1072 | 50.9 (15.8) |
P value = 0.0781 (Fisher's exact test), Q value = 0.18
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
10Q GAIN MUTATED | 3 | 9 |
10Q GAIN WILD-TYPE | 570 | 503 |
P value = 0.0434 (Fisher's exact test), Q value = 0.11
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
10Q GAIN MUTATED | 7 | 0 | 0 | 2 | 0 | 3 |
10Q GAIN WILD-TYPE | 187 | 30 | 129 | 187 | 18 | 522 |
P value = 0.0861 (Fisher's exact test), Q value = 0.19
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
10Q GAIN MUTATED | 2 | 9 |
10Q GAIN WILD-TYPE | 42 | 912 |
P value = 0.0561 (logrank test), Q value = 0.14
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
11P GAIN MUTATED | 49 | 21 | 1.2 - 211.2 (19.8) |
11P GAIN WILD-TYPE | 1029 | 577 | 0.0 - 182.3 (15.9) |
P value = 0.0122 (Fisher's exact test), Q value = 0.038
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
11P GAIN MUTATED | 17 | 32 |
11P GAIN WILD-TYPE | 556 | 480 |
P value = 0.12 (Wilcoxon-test), Q value = 0.24
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
11P GAIN MUTATED | 35 | 84.9 (13.6) |
11P GAIN WILD-TYPE | 697 | 80.9 (15.4) |
P value = 0.0184 (Fisher's exact test), Q value = 0.054
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
11P GAIN MUTATED | 6 | 0 | 9 | 17 | 0 | 17 |
11P GAIN WILD-TYPE | 188 | 30 | 120 | 172 | 18 | 508 |
P value = 1.79e-05 (logrank test), Q value = 0.00012
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
11Q GAIN MUTATED | 74 | 24 | 1.2 - 211.2 (23.0) |
11Q GAIN WILD-TYPE | 1004 | 574 | 0.0 - 172.8 (15.4) |
P value = 0.0123 (Wilcoxon-test), Q value = 0.039
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
11Q GAIN MUTATED | 74 | 46.5 (14.1) |
11Q GAIN WILD-TYPE | 1010 | 51.1 (15.9) |
P value = 4.43e-09 (Fisher's exact test), Q value = 6.7e-08
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
11Q GAIN MUTATED | 15 | 59 |
11Q GAIN WILD-TYPE | 558 | 453 |
P value = 0.00725 (Wilcoxon-test), Q value = 0.024
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
11Q GAIN MUTATED | 47 | 86.8 (11.2) |
11Q GAIN WILD-TYPE | 685 | 80.7 (15.5) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
11Q GAIN MUTATED | 18 | 0 | 14 | 27 | 1 | 14 |
11Q GAIN WILD-TYPE | 176 | 30 | 115 | 162 | 17 | 511 |
P value = 0.0221 (Fisher's exact test), Q value = 0.064
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
12P GAIN MUTATED | 60 | 33 |
12P GAIN WILD-TYPE | 513 | 479 |
P value = 0.000447 (Fisher's exact test), Q value = 0.0021
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
12P GAIN MUTATED | 9 | 79 |
12P GAIN WILD-TYPE | 249 | 691 |
P value = 0.00123 (logrank test), Q value = 0.0052
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
12Q GAIN MUTATED | 64 | 49 | 1.1 - 84.3 (14.7) |
12Q GAIN WILD-TYPE | 1014 | 549 | 0.0 - 211.2 (16.1) |
P value = 0.0694 (Wilcoxon-test), Q value = 0.16
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
12Q GAIN MUTATED | 65 | 53.9 (15.9) |
12Q GAIN WILD-TYPE | 1019 | 50.6 (15.8) |
P value = 0.000165 (Fisher's exact test), Q value = 0.00084
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
12Q GAIN MUTATED | 49 | 16 |
12Q GAIN WILD-TYPE | 524 | 496 |
P value = 0.00943 (Fisher's exact test), Q value = 0.03
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
12Q GAIN MUTATED | 7 | 54 |
12Q GAIN WILD-TYPE | 251 | 716 |
P value = 0.0739 (Wilcoxon-test), Q value = 0.17
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
12Q GAIN MUTATED | 46 | 76.7 (18.1) |
12Q GAIN WILD-TYPE | 686 | 81.4 (15.0) |
P value = 0.00525 (Fisher's exact test), Q value = 0.018
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
12Q GAIN MUTATED | 5 | 3 | 4 | 7 | 0 | 46 |
12Q GAIN WILD-TYPE | 189 | 27 | 125 | 182 | 18 | 479 |
P value = 0.118 (Fisher's exact test), Q value = 0.24
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
12Q GAIN MUTATED | 0 | 4 | 4 | 54 |
12Q GAIN WILD-TYPE | 1 | 17 | 67 | 905 |
P value = 0.0741 (Wilcoxon-test), Q value = 0.17
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
13Q GAIN MUTATED | 17 | 57.6 (17.7) |
13Q GAIN WILD-TYPE | 1067 | 50.7 (15.7) |
P value = 0.069 (Fisher's exact test), Q value = 0.16
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
13Q GAIN MUTATED | 7 | 8 |
13Q GAIN WILD-TYPE | 251 | 762 |
P value = 0.021 (Wilcoxon-test), Q value = 0.061
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
13Q GAIN MUTATED | 14 | 72.1 (14.8) |
13Q GAIN WILD-TYPE | 718 | 81.3 (15.3) |
P value = 0.00183 (logrank test), Q value = 0.0073
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
14Q GAIN MUTATED | 26 | 22 | 0.4 - 51.5 (10.4) |
14Q GAIN WILD-TYPE | 1052 | 576 | 0.0 - 211.2 (16.0) |
P value = 0.00035 (Wilcoxon-test), Q value = 0.0017
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
14Q GAIN MUTATED | 26 | 61.4 (14.5) |
14Q GAIN WILD-TYPE | 1058 | 50.6 (15.7) |
P value = 0.00105 (Fisher's exact test), Q value = 0.0045
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
14Q GAIN MUTATED | 22 | 4 |
14Q GAIN WILD-TYPE | 551 | 508 |
P value = 0.0066 (Fisher's exact test), Q value = 0.022
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
14Q GAIN MUTATED | 2 | 2 | 1 | 1 | 2 | 18 |
14Q GAIN WILD-TYPE | 192 | 28 | 128 | 188 | 16 | 507 |
P value = 0.00596 (logrank test), Q value = 0.02
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
15Q GAIN MUTATED | 37 | 30 | 0.2 - 117.4 (14.5) |
15Q GAIN WILD-TYPE | 1041 | 568 | 0.0 - 211.2 (16.0) |
P value = 0.064 (Wilcoxon-test), Q value = 0.15
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
15Q GAIN MUTATED | 37 | 55.0 (13.3) |
15Q GAIN WILD-TYPE | 1047 | 50.7 (15.9) |
P value = 0.0926 (Fisher's exact test), Q value = 0.2
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
15Q GAIN MUTATED | 25 | 12 |
15Q GAIN WILD-TYPE | 548 | 500 |
P value = 0.00771 (Wilcoxon-test), Q value = 0.025
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
15Q GAIN MUTATED | 29 | 73.8 (15.7) |
15Q GAIN WILD-TYPE | 703 | 81.4 (15.2) |
P value = 0.0572 (Wilcoxon-test), Q value = 0.14
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
16P GAIN MUTATED | 54 | 54.5 (14.8) |
16P GAIN WILD-TYPE | 1030 | 50.6 (15.8) |
P value = 0.00793 (Fisher's exact test), Q value = 0.026
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
16P GAIN MUTATED | 38 | 16 |
16P GAIN WILD-TYPE | 535 | 496 |
P value = 0.049 (Fisher's exact test), Q value = 0.12
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
16P GAIN MUTATED | 7 | 45 |
16P GAIN WILD-TYPE | 251 | 725 |
P value = 0.0411 (Fisher's exact test), Q value = 0.11
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
16P GAIN MUTATED | 10 | 1 | 2 | 4 | 1 | 36 |
16P GAIN WILD-TYPE | 184 | 29 | 127 | 185 | 17 | 489 |
P value = 0.0401 (Fisher's exact test), Q value = 0.11
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
16Q GAIN MUTATED | 38 | 19 |
16Q GAIN WILD-TYPE | 535 | 493 |
P value = 0.0189 (Fisher's exact test), Q value = 0.055
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
16Q GAIN MUTATED | 13 | 1 | 1 | 5 | 1 | 36 |
16Q GAIN WILD-TYPE | 181 | 29 | 128 | 184 | 17 | 489 |
P value = 2.65e-05 (logrank test), Q value = 0.00017
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
17P GAIN MUTATED | 72 | 54 | 0.2 - 72.4 (14.2) |
17P GAIN WILD-TYPE | 1006 | 544 | 0.0 - 211.2 (16.2) |
P value = 7.01e-06 (Wilcoxon-test), Q value = 6.4e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
17P GAIN MUTATED | 72 | 58.6 (15.0) |
17P GAIN WILD-TYPE | 1012 | 50.3 (15.7) |
P value = 0.00144 (Fisher's exact test), Q value = 0.0059
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
17P GAIN MUTATED | 51 | 21 |
17P GAIN WILD-TYPE | 522 | 491 |
P value = 0.0261 (Fisher's exact test), Q value = 0.073
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
17P GAIN MUTATED | 21 | 51 |
17P GAIN WILD-TYPE | 432 | 581 |
P value = 0.00382 (Fisher's exact test), Q value = 0.014
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
17P GAIN MUTATED | 11 | 4 | 1 | 9 | 1 | 46 |
17P GAIN WILD-TYPE | 183 | 26 | 128 | 180 | 17 | 479 |
P value = 5.63e-07 (logrank test), Q value = 6.8e-06
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
17Q GAIN MUTATED | 86 | 66 | 0.2 - 72.4 (13.6) |
17Q GAIN WILD-TYPE | 992 | 532 | 0.0 - 211.2 (16.2) |
P value = 6.2e-06 (Wilcoxon-test), Q value = 5.9e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
17Q GAIN MUTATED | 86 | 58.0 (15.4) |
17Q GAIN WILD-TYPE | 998 | 50.2 (15.7) |
P value = 0.000445 (Fisher's exact test), Q value = 0.0021
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
17Q GAIN MUTATED | 61 | 25 |
17Q GAIN WILD-TYPE | 512 | 487 |
P value = 0.087 (Fisher's exact test), Q value = 0.19
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
17Q GAIN MUTATED | 28 | 58 |
17Q GAIN WILD-TYPE | 425 | 574 |
P value = 0.00571 (Fisher's exact test), Q value = 0.02
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
17Q GAIN MUTATED | 13 | 4 | 3 | 9 | 2 | 55 |
17Q GAIN WILD-TYPE | 181 | 26 | 126 | 180 | 16 | 470 |
P value = 5.89e-05 (logrank test), Q value = 0.00034
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
18P GAIN MUTATED | 78 | 59 | 0.1 - 117.5 (14.3) |
18P GAIN WILD-TYPE | 1000 | 539 | 0.0 - 211.2 (16.2) |
P value = 0.0145 (Wilcoxon-test), Q value = 0.045
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
18P GAIN MUTATED | 78 | 55.0 (17.1) |
18P GAIN WILD-TYPE | 1006 | 50.5 (15.7) |
P value = 8.22e-05 (Fisher's exact test), Q value = 0.00045
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
18P GAIN MUTATED | 58 | 20 |
18P GAIN WILD-TYPE | 515 | 492 |
P value = 0.0164 (Wilcoxon-test), Q value = 0.049
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
18P GAIN MUTATED | 49 | 74.3 (20.5) |
18P GAIN WILD-TYPE | 683 | 81.6 (14.7) |
P value = 0.00074 (Fisher's exact test), Q value = 0.0033
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
18P GAIN MUTATED | 11 | 1 | 4 | 5 | 0 | 57 |
18P GAIN WILD-TYPE | 183 | 29 | 125 | 184 | 18 | 468 |
P value = 2.6e-06 (logrank test), Q value = 2.9e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
18Q GAIN MUTATED | 75 | 59 | 0.1 - 65.0 (13.3) |
18Q GAIN WILD-TYPE | 1003 | 539 | 0.0 - 211.2 (16.2) |
P value = 0.00142 (Wilcoxon-test), Q value = 0.0058
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
18Q GAIN MUTATED | 75 | 56.3 (16.4) |
18Q GAIN WILD-TYPE | 1009 | 50.4 (15.7) |
P value = 2.03e-06 (Fisher's exact test), Q value = 2.3e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
18Q GAIN MUTATED | 59 | 16 |
18Q GAIN WILD-TYPE | 514 | 496 |
P value = 0.0485 (Fisher's exact test), Q value = 0.12
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
18Q GAIN MUTATED | 11 | 61 |
18Q GAIN WILD-TYPE | 247 | 709 |
P value = 0.022 (Wilcoxon-test), Q value = 0.064
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
18Q GAIN MUTATED | 49 | 75.1 (19.7) |
18Q GAIN WILD-TYPE | 683 | 81.5 (14.8) |
P value = 2e-05 (Fisher's exact test), Q value = 0.00013
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
18Q GAIN MUTATED | 10 | 1 | 3 | 3 | 0 | 58 |
18Q GAIN WILD-TYPE | 184 | 29 | 126 | 186 | 18 | 467 |
P value = 5.1e-06 (logrank test), Q value = 5e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
19P GAIN MUTATED | 318 | 209 | 0.1 - 169.8 (15.4) |
19P GAIN WILD-TYPE | 760 | 389 | 0.0 - 211.2 (16.3) |
P value = 3.12e-07 (Wilcoxon-test), Q value = 3.9e-06
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
19P GAIN MUTATED | 321 | 54.6 (14.3) |
19P GAIN WILD-TYPE | 763 | 49.2 (16.1) |
P value = 4.73e-13 (Fisher's exact test), Q value = 9.7e-12
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
19P GAIN MUTATED | 224 | 98 |
19P GAIN WILD-TYPE | 349 | 414 |
P value = 0.0585 (Fisher's exact test), Q value = 0.14
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
19P GAIN MUTATED | 64 | 240 |
19P GAIN WILD-TYPE | 194 | 530 |
P value = 0.0229 (Wilcoxon-test), Q value = 0.066
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
19P GAIN MUTATED | 213 | 79.5 (15.4) |
19P GAIN WILD-TYPE | 519 | 81.7 (15.2) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
19P GAIN MUTATED | 21 | 13 | 19 | 58 | 10 | 201 |
19P GAIN WILD-TYPE | 173 | 17 | 110 | 131 | 8 | 324 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
19Q GAIN MUTATED | 220 | 173 | 0.1 - 92.7 (14.5) |
19Q GAIN WILD-TYPE | 858 | 425 | 0.0 - 211.2 (16.6) |
P value = 5.33e-16 (Wilcoxon-test), Q value = 1.3e-14
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
19Q GAIN MUTATED | 222 | 58.4 (12.4) |
19Q GAIN WILD-TYPE | 862 | 48.9 (16.0) |
P value = 7.04e-35 (Fisher's exact test), Q value = 2.6e-33
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
19Q GAIN MUTATED | 195 | 27 |
19Q GAIN WILD-TYPE | 378 | 485 |
P value = 2.74e-06 (Fisher's exact test), Q value = 3e-05
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
19Q GAIN MUTATED | 27 | 181 |
19Q GAIN WILD-TYPE | 231 | 589 |
P value = 5.35e-05 (Wilcoxon-test), Q value = 0.00032
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
19Q GAIN MUTATED | 153 | 77.6 (14.3) |
19Q GAIN WILD-TYPE | 579 | 82.0 (15.4) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
19Q GAIN MUTATED | 13 | 11 | 9 | 5 | 7 | 177 |
19Q GAIN WILD-TYPE | 181 | 19 | 120 | 184 | 11 | 348 |
P value = 0.0134 (Fisher's exact test), Q value = 0.042
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
19Q GAIN MUTATED | 0 | 8 | 22 | 185 |
19Q GAIN WILD-TYPE | 1 | 13 | 49 | 774 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
20P GAIN MUTATED | 263 | 213 | 0.1 - 94.8 (13.9) |
20P GAIN WILD-TYPE | 815 | 385 | 0.0 - 211.2 (17.3) |
P value = 4.89e-28 (Wilcoxon-test), Q value = 1.6e-26
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
20P GAIN MUTATED | 265 | 59.9 (13.0) |
20P GAIN WILD-TYPE | 819 | 47.9 (15.5) |
P value = 1.82e-32 (Fisher's exact test), Q value = 6.4e-31
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
20P GAIN MUTATED | 221 | 44 |
20P GAIN WILD-TYPE | 352 | 468 |
P value = 2.51e-05 (Fisher's exact test), Q value = 0.00016
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
20P GAIN MUTATED | 38 | 211 |
20P GAIN WILD-TYPE | 220 | 559 |
P value = 2.08e-05 (Wilcoxon-test), Q value = 0.00013
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
20P GAIN MUTATED | 191 | 77.5 (15.5) |
20P GAIN WILD-TYPE | 541 | 82.3 (15.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
20P GAIN MUTATED | 23 | 10 | 8 | 13 | 9 | 202 |
20P GAIN WILD-TYPE | 171 | 20 | 121 | 176 | 9 | 323 |
P value = 0.0859 (Fisher's exact test), Q value = 0.19
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
20P GAIN MUTATED | 0 | 10 | 18 | 231 |
20P GAIN WILD-TYPE | 1 | 11 | 53 | 728 |
P value = 0.106 (Fisher's exact test), Q value = 0.22
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
20P GAIN MUTATED | 6 | 230 |
20P GAIN WILD-TYPE | 38 | 691 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
20Q GAIN MUTATED | 261 | 211 | 0.1 - 117.5 (13.9) |
20Q GAIN WILD-TYPE | 817 | 387 | 0.0 - 211.2 (17.2) |
P value = 1.01e-26 (Wilcoxon-test), Q value = 3.1e-25
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
20Q GAIN MUTATED | 262 | 59.8 (13.2) |
20Q GAIN WILD-TYPE | 822 | 47.9 (15.5) |
P value = 2.26e-32 (Fisher's exact test), Q value = 7.6e-31
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
20Q GAIN MUTATED | 219 | 43 |
20Q GAIN WILD-TYPE | 354 | 469 |
P value = 1.61e-05 (Fisher's exact test), Q value = 0.00011
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
20Q GAIN MUTATED | 37 | 211 |
20Q GAIN WILD-TYPE | 221 | 559 |
P value = 6.72e-06 (Wilcoxon-test), Q value = 6.3e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
20Q GAIN MUTATED | 190 | 77.4 (15.3) |
20Q GAIN WILD-TYPE | 542 | 82.4 (15.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
20Q GAIN MUTATED | 22 | 10 | 7 | 14 | 9 | 200 |
20Q GAIN WILD-TYPE | 172 | 20 | 122 | 175 | 9 | 325 |
P value = 0.0777 (Fisher's exact test), Q value = 0.18
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
20Q GAIN MUTATED | 0 | 10 | 18 | 228 |
20Q GAIN WILD-TYPE | 1 | 11 | 53 | 731 |
P value = 0.106 (Fisher's exact test), Q value = 0.22
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
20Q GAIN MUTATED | 6 | 229 |
20Q GAIN WILD-TYPE | 38 | 692 |
P value = 0.00316 (logrank test), Q value = 0.012
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
21Q GAIN MUTATED | 88 | 65 | 0.2 - 211.2 (14.4) |
21Q GAIN WILD-TYPE | 990 | 533 | 0.0 - 182.3 (16.2) |
P value = 9.77e-07 (Wilcoxon-test), Q value = 1.2e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
21Q GAIN MUTATED | 88 | 58.8 (14.4) |
21Q GAIN WILD-TYPE | 996 | 50.1 (15.7) |
P value = 8.45e-05 (Fisher's exact test), Q value = 0.00046
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
21Q GAIN MUTATED | 64 | 24 |
21Q GAIN WILD-TYPE | 509 | 488 |
P value = 0.0177 (Fisher's exact test), Q value = 0.053
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
21Q GAIN MUTATED | 12 | 71 |
21Q GAIN WILD-TYPE | 246 | 699 |
P value = 0.109 (Wilcoxon-test), Q value = 0.23
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
21Q GAIN MUTATED | 66 | 78.0 (17.1) |
21Q GAIN WILD-TYPE | 666 | 81.4 (15.1) |
P value = 0.00082 (Fisher's exact test), Q value = 0.0036
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
21Q GAIN MUTATED | 9 | 7 | 5 | 10 | 1 | 56 |
21Q GAIN WILD-TYPE | 185 | 23 | 124 | 179 | 17 | 469 |
P value = 0.096 (Fisher's exact test), Q value = 0.2
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
21Q GAIN MUTATED | 0 | 5 | 6 | 76 |
21Q GAIN WILD-TYPE | 1 | 16 | 65 | 883 |
P value = 0.0446 (Fisher's exact test), Q value = 0.12
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
21Q GAIN MUTATED | 0 | 81 |
21Q GAIN WILD-TYPE | 44 | 840 |
P value = 0.076 (Wilcoxon-test), Q value = 0.17
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
22Q GAIN MUTATED | 33 | 77.6 (12.5) |
22Q GAIN WILD-TYPE | 699 | 81.2 (15.4) |
P value = 0.00903 (Fisher's exact test), Q value = 0.029
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
22Q GAIN MUTATED | 3 | 0 | 4 | 17 | 0 | 33 |
22Q GAIN WILD-TYPE | 191 | 30 | 125 | 172 | 18 | 492 |
P value = 0.0665 (Fisher's exact test), Q value = 0.16
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
22Q GAIN MUTATED | 5 | 44 |
22Q GAIN WILD-TYPE | 39 | 877 |
P value = 0.0866 (logrank test), Q value = 0.19
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
XP GAIN MUTATED | 35 | 15 | 0.9 - 69.3 (20.0) |
XP GAIN WILD-TYPE | 1043 | 583 | 0.0 - 211.2 (15.9) |
P value = 0.00236 (logrank test), Q value = 0.0091
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
XQ GAIN MUTATED | 57 | 22 | 0.1 - 130.8 (20.8) |
XQ GAIN WILD-TYPE | 1021 | 576 | 0.0 - 211.2 (15.8) |
P value = 0.000335 (Wilcoxon-test), Q value = 0.0016
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
XQ GAIN MUTATED | 57 | 43.6 (16.2) |
XQ GAIN WILD-TYPE | 1027 | 51.2 (15.7) |
P value = 0.000358 (Fisher's exact test), Q value = 0.0017
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
XQ GAIN MUTATED | 17 | 40 |
XQ GAIN WILD-TYPE | 556 | 472 |
P value = 0.0534 (Fisher's exact test), Q value = 0.13
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
XQ GAIN MUTATED | 31 | 26 |
XQ GAIN WILD-TYPE | 422 | 606 |
P value = 0.028 (Wilcoxon-test), Q value = 0.077
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
XQ GAIN MUTATED | 31 | 86.5 (12.8) |
XQ GAIN WILD-TYPE | 701 | 80.8 (15.4) |
P value = 0.00019 (Fisher's exact test), Q value = 0.00095
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
XQ GAIN MUTATED | 19 | 1 | 15 | 6 | 1 | 15 |
XQ GAIN WILD-TYPE | 175 | 29 | 114 | 183 | 17 | 510 |
P value = 0.00399 (Fisher's exact test), Q value = 0.014
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
XQ GAIN MUTATED | 7 | 40 |
XQ GAIN WILD-TYPE | 37 | 881 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
1P LOSS MUTATED | 197 | 41 | 0.1 - 182.3 (22.5) |
1P LOSS WILD-TYPE | 881 | 557 | 0.0 - 211.2 (15.0) |
P value = 3.46e-05 (Wilcoxon-test), Q value = 0.00021
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
1P LOSS MUTATED | 199 | 46.8 (13.6) |
1P LOSS WILD-TYPE | 885 | 51.7 (16.1) |
P value = 4.74e-51 (Fisher's exact test), Q value = 1.9e-49
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
1P LOSS MUTATED | 15 | 185 |
1P LOSS WILD-TYPE | 558 | 327 |
P value = 1.16e-18 (Fisher's exact test), Q value = 3.2e-17
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
1P LOSS MUTATED | 97 | 90 |
1P LOSS WILD-TYPE | 161 | 680 |
P value = 2.88e-06 (Wilcoxon-test), Q value = 3.1e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
1P LOSS MUTATED | 121 | 86.0 (15.0) |
1P LOSS WILD-TYPE | 611 | 80.1 (15.2) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
1P LOSS MUTATED | 10 | 1 | 40 | 135 | 1 | 13 |
1P LOSS WILD-TYPE | 184 | 29 | 89 | 54 | 17 | 512 |
P value = 0.0844 (Fisher's exact test), Q value = 0.19
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
1P LOSS MUTATED | 0 | 5 | 6 | 182 |
1P LOSS WILD-TYPE | 1 | 16 | 65 | 777 |
P value = 0.0571 (logrank test), Q value = 0.14
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
1Q LOSS MUTATED | 46 | 22 | 0.2 - 169.8 (18.4) |
1Q LOSS WILD-TYPE | 1032 | 576 | 0.0 - 211.2 (16.0) |
P value = 0.00616 (Fisher's exact test), Q value = 0.021
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
1Q LOSS MUTATED | 15 | 31 |
1Q LOSS WILD-TYPE | 558 | 481 |
P value = 0.0719 (Fisher's exact test), Q value = 0.17
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
1Q LOSS MUTATED | 16 | 27 |
1Q LOSS WILD-TYPE | 242 | 743 |
P value = 0.00024 (Fisher's exact test), Q value = 0.0012
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
1Q LOSS MUTATED | 4 | 1 | 6 | 21 | 0 | 14 |
1Q LOSS WILD-TYPE | 190 | 29 | 123 | 168 | 18 | 511 |
P value = 0.0661 (Wilcoxon-test), Q value = 0.16
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
2P LOSS MUTATED | 54 | 54.5 (17.0) |
2P LOSS WILD-TYPE | 1030 | 50.6 (15.7) |
P value = 0.12 (Fisher's exact test), Q value = 0.24
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
2Q LOSS MUTATED | 33 | 19 |
2Q LOSS WILD-TYPE | 540 | 493 |
P value = 0.073 (Fisher's exact test), Q value = 0.17
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
2Q LOSS MUTATED | 12 | 3 | 4 | 3 | 1 | 29 |
2Q LOSS WILD-TYPE | 182 | 27 | 125 | 186 | 17 | 496 |
P value = 0.0272 (Fisher's exact test), Q value = 0.075
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
3P LOSS MUTATED | 9 | 57 |
3P LOSS WILD-TYPE | 249 | 713 |
P value = 0.0339 (Wilcoxon-test), Q value = 0.092
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
3P LOSS MUTATED | 52 | 77.7 (13.2) |
3P LOSS WILD-TYPE | 680 | 81.3 (15.4) |
P value = 0.115 (Fisher's exact test), Q value = 0.24
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
3Q LOSS MUTATED | 9 | 48 |
3Q LOSS WILD-TYPE | 249 | 722 |
P value = 0.0548 (logrank test), Q value = 0.14
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
4P LOSS MUTATED | 127 | 64 | 0.1 - 139.0 (18.0) |
4P LOSS WILD-TYPE | 951 | 534 | 0.0 - 211.2 (15.7) |
P value = 0.0378 (Fisher's exact test), Q value = 0.1
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
4P LOSS MUTATED | 56 | 71 |
4P LOSS WILD-TYPE | 517 | 441 |
P value = 0.0355 (Fisher's exact test), Q value = 0.096
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
4P LOSS MUTATED | 42 | 85 |
4P LOSS WILD-TYPE | 411 | 547 |
P value = 0.00037 (Fisher's exact test), Q value = 0.0018
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
4P LOSS MUTATED | 13 | 3 | 19 | 39 | 0 | 53 |
4P LOSS WILD-TYPE | 181 | 27 | 110 | 150 | 18 | 472 |
P value = 9.07e-05 (logrank test), Q value = 0.00048
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
4Q LOSS MUTATED | 149 | 63 | 0.1 - 156.2 (21.3) |
4Q LOSS WILD-TYPE | 929 | 535 | 0.0 - 211.2 (15.3) |
P value = 0.0177 (Wilcoxon-test), Q value = 0.053
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
4Q LOSS MUTATED | 149 | 48.0 (14.4) |
4Q LOSS WILD-TYPE | 935 | 51.3 (16.0) |
P value = 6.59e-05 (Fisher's exact test), Q value = 0.00037
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
4Q LOSS MUTATED | 56 | 93 |
4Q LOSS WILD-TYPE | 517 | 419 |
P value = 0.046 (Fisher's exact test), Q value = 0.12
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
4Q LOSS MUTATED | 45 | 95 |
4Q LOSS WILD-TYPE | 213 | 675 |
P value = 8e-05 (Fisher's exact test), Q value = 0.00044
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
4Q LOSS MUTATED | 24 | 4 | 23 | 46 | 1 | 51 |
4Q LOSS WILD-TYPE | 170 | 26 | 106 | 143 | 17 | 474 |
P value = 0.0021 (Fisher's exact test), Q value = 0.0083
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
5P LOSS MUTATED | 8 | 67 |
5P LOSS WILD-TYPE | 250 | 703 |
P value = 0.0472 (Fisher's exact test), Q value = 0.12
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
5P LOSS MUTATED | 20 | 1 | 11 | 5 | 1 | 42 |
5P LOSS WILD-TYPE | 174 | 29 | 118 | 184 | 17 | 483 |
P value = 0.00073 (Fisher's exact test), Q value = 0.0032
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
5Q LOSS MUTATED | 7 | 67 |
5Q LOSS WILD-TYPE | 251 | 703 |
P value = 0.0847 (Fisher's exact test), Q value = 0.19
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
5Q LOSS MUTATED | 20 | 1 | 7 | 7 | 0 | 45 |
5Q LOSS WILD-TYPE | 174 | 29 | 122 | 182 | 18 | 480 |
P value = 1.14e-12 (logrank test), Q value = 2.2e-11
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
6P LOSS MUTATED | 117 | 90 | 0.2 - 92.7 (11.7) |
6P LOSS WILD-TYPE | 961 | 508 | 0.0 - 211.2 (16.8) |
P value = 0.000125 (Wilcoxon-test), Q value = 0.00064
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
6P LOSS MUTATED | 117 | 56.0 (15.0) |
6P LOSS WILD-TYPE | 967 | 50.2 (15.8) |
P value = 5.11e-06 (Fisher's exact test), Q value = 5e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
6P LOSS MUTATED | 85 | 32 |
6P LOSS WILD-TYPE | 488 | 480 |
P value = 0.0865 (Wilcoxon-test), Q value = 0.19
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
6P LOSS MUTATED | 86 | 78.8 (15.1) |
6P LOSS WILD-TYPE | 646 | 81.4 (15.3) |
P value = 8e-05 (Fisher's exact test), Q value = 0.00044
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
6P LOSS MUTATED | 15 | 3 | 4 | 13 | 3 | 79 |
6P LOSS WILD-TYPE | 179 | 27 | 125 | 176 | 15 | 446 |
P value = 0.0437 (Fisher's exact test), Q value = 0.11
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
6P LOSS MUTATED | 1 | 4 | 10 | 99 |
6P LOSS WILD-TYPE | 0 | 17 | 61 | 860 |
P value = 1.41e-08 (logrank test), Q value = 2e-07
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
6Q LOSS MUTATED | 186 | 127 | 0.1 - 94.8 (13.9) |
6Q LOSS WILD-TYPE | 892 | 471 | 0.0 - 211.2 (16.8) |
P value = 0.000709 (Wilcoxon-test), Q value = 0.0032
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
6Q LOSS MUTATED | 188 | 54.3 (15.0) |
6Q LOSS WILD-TYPE | 896 | 50.1 (15.9) |
P value = 3.86e-05 (Fisher's exact test), Q value = 0.00023
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
6Q LOSS MUTATED | 125 | 63 |
6Q LOSS WILD-TYPE | 448 | 449 |
P value = 0.0686 (Fisher's exact test), Q value = 0.16
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
6Q LOSS MUTATED | 34 | 141 |
6Q LOSS WILD-TYPE | 224 | 629 |
P value = 0.00389 (Wilcoxon-test), Q value = 0.014
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
6Q LOSS MUTATED | 136 | 78.1 (15.7) |
6Q LOSS WILD-TYPE | 596 | 81.8 (15.1) |
P value = 2e-05 (Fisher's exact test), Q value = 0.00013
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
6Q LOSS MUTATED | 37 | 6 | 10 | 16 | 4 | 115 |
6Q LOSS WILD-TYPE | 157 | 24 | 119 | 173 | 14 | 410 |
P value = 0.0176 (Fisher's exact test), Q value = 0.053
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
6Q LOSS MUTATED | 1 | 6 | 18 | 157 |
6Q LOSS WILD-TYPE | 0 | 15 | 53 | 802 |
P value = 0.0954 (Fisher's exact test), Q value = 0.2
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
6Q LOSS MUTATED | 3 | 159 |
6Q LOSS WILD-TYPE | 41 | 762 |
P value = 0.0919 (Wilcoxon-test), Q value = 0.2
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
7Q LOSS MUTATED | 9 | 41.6 (17.8) |
7Q LOSS WILD-TYPE | 1075 | 50.9 (15.8) |
P value = 0.000115 (logrank test), Q value = 6e-04
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
8P LOSS MUTATED | 74 | 52 | 0.2 - 120.6 (11.8) |
8P LOSS WILD-TYPE | 1004 | 546 | 0.0 - 211.2 (16.4) |
P value = 0.000279 (Wilcoxon-test), Q value = 0.0014
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
8P LOSS MUTATED | 75 | 57.1 (14.4) |
8P LOSS WILD-TYPE | 1009 | 50.3 (15.8) |
P value = 7.01e-06 (Fisher's exact test), Q value = 6.4e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
8P LOSS MUTATED | 58 | 17 |
8P LOSS WILD-TYPE | 515 | 495 |
P value = 0.00613 (Fisher's exact test), Q value = 0.021
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
8P LOSS MUTATED | 8 | 62 |
8P LOSS WILD-TYPE | 250 | 708 |
P value = 0.00031 (Fisher's exact test), Q value = 0.0015
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
8P LOSS MUTATED | 9 | 1 | 4 | 4 | 1 | 56 |
8P LOSS WILD-TYPE | 185 | 29 | 125 | 185 | 17 | 469 |
P value = 0.00581 (Fisher's exact test), Q value = 0.02
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
8P LOSS MUTATED | 0 | 6 | 4 | 60 |
8P LOSS WILD-TYPE | 1 | 15 | 67 | 899 |
P value = 4.28e-06 (logrank test), Q value = 4.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
8Q LOSS MUTATED | 52 | 38 | 0.2 - 58.8 (11.6) |
8Q LOSS WILD-TYPE | 1026 | 560 | 0.0 - 211.2 (16.4) |
P value = 0.000324 (Wilcoxon-test), Q value = 0.0016
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
8Q LOSS MUTATED | 52 | 58.5 (12.7) |
8Q LOSS WILD-TYPE | 1032 | 50.4 (15.8) |
P value = 9.33e-05 (Fisher's exact test), Q value = 0.00049
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
8Q LOSS MUTATED | 41 | 11 |
8Q LOSS WILD-TYPE | 532 | 501 |
P value = 0.016 (Fisher's exact test), Q value = 0.049
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
8Q LOSS MUTATED | 5 | 43 |
8Q LOSS WILD-TYPE | 253 | 727 |
P value = 0.00489 (Fisher's exact test), Q value = 0.017
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
8Q LOSS MUTATED | 5 | 1 | 3 | 3 | 1 | 39 |
8Q LOSS WILD-TYPE | 189 | 29 | 126 | 186 | 17 | 486 |
P value = 5.34e-06 (logrank test), Q value = 5.1e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
9P LOSS MUTATED | 313 | 211 | 0.1 - 169.8 (15.3) |
9P LOSS WILD-TYPE | 765 | 387 | 0.0 - 211.2 (16.4) |
P value = 9.23e-05 (Wilcoxon-test), Q value = 0.00049
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
9P LOSS MUTATED | 315 | 53.8 (15.3) |
9P LOSS WILD-TYPE | 769 | 49.6 (15.8) |
P value = 9.65e-06 (Fisher's exact test), Q value = 6.9e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
9P LOSS MUTATED | 200 | 116 |
9P LOSS WILD-TYPE | 373 | 396 |
P value = 0.000449 (Fisher's exact test), Q value = 0.0021
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
9P LOSS MUTATED | 52 | 243 |
9P LOSS WILD-TYPE | 206 | 527 |
P value = 0.0355 (Wilcoxon-test), Q value = 0.096
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
9P LOSS MUTATED | 213 | 78.9 (16.9) |
9P LOSS WILD-TYPE | 519 | 82.0 (14.5) |
P value = 6e-05 (Fisher's exact test), Q value = 0.00034
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
9P LOSS MUTATED | 55 | 12 | 23 | 38 | 6 | 182 |
9P LOSS WILD-TYPE | 139 | 18 | 106 | 151 | 12 | 343 |
P value = 0.119 (Fisher's exact test), Q value = 0.24
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
9P LOSS MUTATED | 0 | 8 | 28 | 271 |
9P LOSS WILD-TYPE | 1 | 13 | 43 | 688 |
P value = 0.0603 (Fisher's exact test), Q value = 0.15
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
9P LOSS MUTATED | 7 | 273 |
9P LOSS WILD-TYPE | 37 | 648 |
P value = 0.00188 (logrank test), Q value = 0.0075
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
9Q LOSS MUTATED | 140 | 96 | 0.1 - 169.8 (14.6) |
9Q LOSS WILD-TYPE | 938 | 502 | 0.0 - 211.2 (16.2) |
P value = 0.00228 (Wilcoxon-test), Q value = 0.0089
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
9Q LOSS MUTATED | 141 | 54.3 (15.6) |
9Q LOSS WILD-TYPE | 943 | 50.3 (15.8) |
P value = 0.00505 (Fisher's exact test), Q value = 0.018
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
9Q LOSS MUTATED | 90 | 51 |
9Q LOSS WILD-TYPE | 483 | 461 |
P value = 0.000949 (Fisher's exact test), Q value = 0.0041
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
9Q LOSS MUTATED | 17 | 109 |
9Q LOSS WILD-TYPE | 241 | 661 |
P value = 0.00123 (Wilcoxon-test), Q value = 0.0052
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
9Q LOSS MUTATED | 93 | 76.8 (14.5) |
9Q LOSS WILD-TYPE | 639 | 81.7 (15.3) |
P value = 0.0506 (Fisher's exact test), Q value = 0.13
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
9Q LOSS MUTATED | 21 | 7 | 11 | 19 | 4 | 79 |
9Q LOSS WILD-TYPE | 173 | 23 | 118 | 170 | 14 | 446 |
P value = 0.0927 (Fisher's exact test), Q value = 0.2
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
9Q LOSS MUTATED | 0 | 3 | 16 | 118 |
9Q LOSS WILD-TYPE | 1 | 18 | 55 | 841 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
10P LOSS MUTATED | 557 | 450 | 0.1 - 134.3 (12.6) |
10P LOSS WILD-TYPE | 521 | 148 | 0.0 - 211.2 (22.7) |
P value = 2.02e-74 (Wilcoxon-test), Q value = 1.1e-72
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
10P LOSS MUTATED | 559 | 59.1 (12.4) |
10P LOSS WILD-TYPE | 525 | 42.0 (14.1) |
P value = 1.94e-116 (Fisher's exact test), Q value = 1.4e-114
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
10P LOSS MUTATED | 476 | 83 |
10P LOSS WILD-TYPE | 97 | 429 |
P value = 0.0846 (Fisher's exact test), Q value = 0.19
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
10P LOSS MUTATED | 219 | 340 |
10P LOSS WILD-TYPE | 234 | 292 |
P value = 1.23e-15 (Fisher's exact test), Q value = 2.9e-14
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
10P LOSS MUTATED | 78 | 453 |
10P LOSS WILD-TYPE | 180 | 317 |
P value = 2.7e-19 (Wilcoxon-test), Q value = 7.7e-18
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
10P LOSS MUTATED | 409 | 76.9 (16.2) |
10P LOSS WILD-TYPE | 323 | 86.3 (12.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
10P LOSS MUTATED | 49 | 23 | 16 | 18 | 10 | 443 |
10P LOSS WILD-TYPE | 145 | 7 | 113 | 171 | 8 | 82 |
P value = 0.00228 (Fisher's exact test), Q value = 0.0089
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
10P LOSS MUTATED | 1 | 9 | 50 | 478 |
10P LOSS WILD-TYPE | 0 | 12 | 21 | 481 |
P value = 0.00298 (Fisher's exact test), Q value = 0.011
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
10P LOSS MUTATED | 12 | 467 |
10P LOSS WILD-TYPE | 32 | 454 |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
10Q LOSS MUTATED | 585 | 465 | 0.1 - 172.8 (12.6) |
10Q LOSS WILD-TYPE | 493 | 133 | 0.0 - 211.2 (23.2) |
P value = 2.15e-68 (Wilcoxon-test), Q value = 1.1e-66
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
10Q LOSS MUTATED | 587 | 58.4 (13.1) |
10Q LOSS WILD-TYPE | 497 | 41.9 (13.9) |
P value = 9.59e-116 (Fisher's exact test), Q value = 6.4e-114
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
10Q LOSS MUTATED | 490 | 97 |
10Q LOSS WILD-TYPE | 83 | 415 |
P value = 1.4e-18 (Fisher's exact test), Q value = 3.7e-17
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
10Q LOSS MUTATED | 79 | 479 |
10Q LOSS WILD-TYPE | 179 | 291 |
P value = 6.88e-21 (Wilcoxon-test), Q value = 2e-19
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
10Q LOSS MUTATED | 428 | 76.9 (16.2) |
10Q LOSS WILD-TYPE | 304 | 86.9 (11.6) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
10Q LOSS MUTATED | 57 | 23 | 19 | 21 | 13 | 454 |
10Q LOSS WILD-TYPE | 137 | 7 | 110 | 168 | 5 | 71 |
P value = 0.004 (Fisher's exact test), Q value = 0.014
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
10Q LOSS MUTATED | 1 | 9 | 51 | 504 |
10Q LOSS WILD-TYPE | 0 | 12 | 20 | 455 |
P value = 0.000617 (Fisher's exact test), Q value = 0.0028
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
10Q LOSS MUTATED | 12 | 494 |
10Q LOSS WILD-TYPE | 32 | 427 |
P value = 0.0404 (Fisher's exact test), Q value = 0.11
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
11P LOSS MUTATED | 98 | 64 |
11P LOSS WILD-TYPE | 475 | 448 |
P value = 0.0246 (Fisher's exact test), Q value = 0.07
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
11P LOSS MUTATED | 81 | 81 |
11P LOSS WILD-TYPE | 372 | 551 |
P value = 0.0115 (Fisher's exact test), Q value = 0.036
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
11P LOSS MUTATED | 26 | 128 |
11P LOSS WILD-TYPE | 232 | 642 |
P value = 0.00042 (Fisher's exact test), Q value = 0.002
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
11P LOSS MUTATED | 38 | 4 | 14 | 12 | 5 | 89 |
11P LOSS WILD-TYPE | 156 | 26 | 115 | 177 | 13 | 436 |
P value = 1.4e-09 (logrank test), Q value = 2.2e-08
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
11Q LOSS MUTATED | 112 | 89 | 0.2 - 92.7 (13.5) |
11Q LOSS WILD-TYPE | 966 | 509 | 0.0 - 211.2 (16.5) |
P value = 8.94e-06 (Wilcoxon-test), Q value = 6.9e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
11Q LOSS MUTATED | 112 | 56.9 (14.2) |
11Q LOSS WILD-TYPE | 972 | 50.1 (15.8) |
P value = 2.35e-10 (Fisher's exact test), Q value = 3.9e-09
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
11Q LOSS MUTATED | 90 | 22 |
11Q LOSS WILD-TYPE | 483 | 490 |
P value = 0.0187 (Fisher's exact test), Q value = 0.055
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
11Q LOSS MUTATED | 17 | 90 |
11Q LOSS WILD-TYPE | 241 | 680 |
P value = 0.033 (Wilcoxon-test), Q value = 0.09
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
11Q LOSS MUTATED | 86 | 78.6 (13.8) |
11Q LOSS WILD-TYPE | 646 | 81.4 (15.5) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
11Q LOSS MUTATED | 14 | 3 | 6 | 2 | 3 | 84 |
11Q LOSS WILD-TYPE | 180 | 27 | 123 | 187 | 15 | 441 |
P value = 0.116 (Fisher's exact test), Q value = 0.24
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
11Q LOSS MUTATED | 1 | 95 |
11Q LOSS WILD-TYPE | 43 | 826 |
P value = 0.00662 (logrank test), Q value = 0.022
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
12P LOSS MUTATED | 83 | 57 | 0.1 - 95.1 (14.9) |
12P LOSS WILD-TYPE | 995 | 541 | 0.0 - 211.2 (16.1) |
P value = 0.0461 (Wilcoxon-test), Q value = 0.12
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
12P LOSS MUTATED | 84 | 54.0 (16.3) |
12P LOSS WILD-TYPE | 1000 | 50.5 (15.7) |
P value = 0.00431 (Fisher's exact test), Q value = 0.015
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
12P LOSS MUTATED | 57 | 27 |
12P LOSS WILD-TYPE | 516 | 485 |
P value = 0.0178 (Fisher's exact test), Q value = 0.053
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
12P LOSS MUTATED | 15 | 1 | 5 | 7 | 1 | 55 |
12P LOSS WILD-TYPE | 179 | 29 | 124 | 182 | 17 | 470 |
P value = 0.0257 (Fisher's exact test), Q value = 0.073
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
12Q LOSS MUTATED | 30 | 1 | 13 | 10 | 2 | 52 |
12Q LOSS WILD-TYPE | 164 | 29 | 116 | 179 | 16 | 473 |
P value = 0.0486 (Fisher's exact test), Q value = 0.12
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
12Q LOSS MUTATED | 0 | 0 | 2 | 103 |
12Q LOSS WILD-TYPE | 1 | 21 | 69 | 856 |
P value = 0.00152 (logrank test), Q value = 0.0062
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
13Q LOSS MUTATED | 298 | 192 | 0.1 - 211.2 (15.0) |
13Q LOSS WILD-TYPE | 780 | 406 | 0.0 - 182.3 (16.8) |
P value = 0.0534 (Wilcoxon-test), Q value = 0.13
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
13Q LOSS MUTATED | 298 | 52.3 (15.7) |
13Q LOSS WILD-TYPE | 786 | 50.3 (15.8) |
P value = 0.000101 (Fisher's exact test), Q value = 0.00053
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
13Q LOSS MUTATED | 186 | 112 |
13Q LOSS WILD-TYPE | 387 | 400 |
P value = 0.0162 (Fisher's exact test), Q value = 0.049
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
13Q LOSS MUTATED | 57 | 230 |
13Q LOSS WILD-TYPE | 201 | 540 |
P value = 0.0959 (Wilcoxon-test), Q value = 0.2
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
13Q LOSS MUTATED | 212 | 79.7 (15.5) |
13Q LOSS WILD-TYPE | 520 | 81.7 (15.2) |
P value = 0.00337 (Fisher's exact test), Q value = 0.013
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
13Q LOSS MUTATED | 48 | 9 | 25 | 39 | 4 | 173 |
13Q LOSS WILD-TYPE | 146 | 21 | 104 | 150 | 14 | 352 |
P value = 5.44e-05 (logrank test), Q value = 0.00032
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
14Q LOSS MUTATED | 224 | 149 | 0.1 - 130.8 (14.8) |
14Q LOSS WILD-TYPE | 854 | 449 | 0.0 - 211.2 (16.5) |
P value = 7.32e-05 (Wilcoxon-test), Q value = 0.00041
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
14Q LOSS MUTATED | 226 | 54.5 (14.9) |
14Q LOSS WILD-TYPE | 858 | 49.9 (15.9) |
P value = 0.000129 (Fisher's exact test), Q value = 0.00066
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
14Q LOSS MUTATED | 145 | 81 |
14Q LOSS WILD-TYPE | 428 | 431 |
P value = 0.0403 (Wilcoxon-test), Q value = 0.11
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
14Q LOSS MUTATED | 165 | 79.6 (14.1) |
14Q LOSS WILD-TYPE | 567 | 81.5 (15.6) |
P value = 0.00109 (Fisher's exact test), Q value = 0.0046
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
14Q LOSS MUTATED | 38 | 5 | 18 | 25 | 6 | 134 |
14Q LOSS WILD-TYPE | 156 | 25 | 111 | 164 | 12 | 391 |
P value = 0.0564 (Fisher's exact test), Q value = 0.14
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
14Q LOSS MUTATED | 1 | 5 | 21 | 192 |
14Q LOSS WILD-TYPE | 0 | 16 | 50 | 767 |
P value = 0.0805 (Fisher's exact test), Q value = 0.18
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
14Q LOSS MUTATED | 4 | 189 |
14Q LOSS WILD-TYPE | 40 | 732 |
P value = 0.00288 (logrank test), Q value = 0.011
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
15Q LOSS MUTATED | 152 | 100 | 0.2 - 134.3 (15.2) |
15Q LOSS WILD-TYPE | 926 | 498 | 0.0 - 211.2 (16.2) |
P value = 5.8e-05 (Wilcoxon-test), Q value = 0.00034
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
15Q LOSS MUTATED | 153 | 55.6 (15.7) |
15Q LOSS WILD-TYPE | 931 | 50.0 (15.7) |
P value = 8.13e-05 (Fisher's exact test), Q value = 0.00044
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
15Q LOSS MUTATED | 104 | 50 |
15Q LOSS WILD-TYPE | 469 | 462 |
P value = 0.00275 (Fisher's exact test), Q value = 0.011
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
15Q LOSS MUTATED | 16 | 7 | 12 | 22 | 2 | 95 |
15Q LOSS WILD-TYPE | 178 | 23 | 117 | 167 | 16 | 430 |
P value = 1.82e-07 (logrank test), Q value = 2.3e-06
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
16P LOSS MUTATED | 78 | 64 | 0.4 - 78.3 (14.4) |
16P LOSS WILD-TYPE | 1000 | 534 | 0.0 - 211.2 (16.2) |
P value = 4.4e-06 (Wilcoxon-test), Q value = 4.4e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
16P LOSS MUTATED | 78 | 58.6 (14.2) |
16P LOSS WILD-TYPE | 1006 | 50.2 (15.8) |
P value = 1.27e-07 (Fisher's exact test), Q value = 1.6e-06
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
16P LOSS MUTATED | 63 | 15 |
16P LOSS WILD-TYPE | 510 | 497 |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
16P LOSS MUTATED | 8 | 1 | 3 | 4 | 0 | 62 |
16P LOSS WILD-TYPE | 186 | 29 | 126 | 185 | 18 | 463 |
P value = 5.86e-08 (logrank test), Q value = 7.9e-07
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
16Q LOSS MUTATED | 104 | 84 | 0.2 - 120.6 (14.4) |
16Q LOSS WILD-TYPE | 974 | 514 | 0.0 - 211.2 (16.3) |
P value = 2.94e-05 (Wilcoxon-test), Q value = 0.00018
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
16Q LOSS MUTATED | 104 | 56.8 (14.4) |
16Q LOSS WILD-TYPE | 980 | 50.2 (15.8) |
P value = 1.23e-08 (Fisher's exact test), Q value = 1.8e-07
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
16Q LOSS MUTATED | 82 | 22 |
16Q LOSS WILD-TYPE | 491 | 490 |
P value = 0.0196 (Fisher's exact test), Q value = 0.057
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
16Q LOSS MUTATED | 15 | 82 |
16Q LOSS WILD-TYPE | 243 | 688 |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
16Q LOSS MUTATED | 11 | 3 | 5 | 6 | 1 | 78 |
16Q LOSS WILD-TYPE | 183 | 27 | 124 | 183 | 17 | 447 |
P value = 7.82e-06 (logrank test), Q value = 6.9e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
17P LOSS MUTATED | 78 | 55 | 0.1 - 92.7 (12.0) |
17P LOSS WILD-TYPE | 1000 | 543 | 0.0 - 211.2 (16.5) |
P value = 0.000118 (Wilcoxon-test), Q value = 0.00061
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
17P LOSS MUTATED | 78 | 57.4 (14.3) |
17P LOSS WILD-TYPE | 1006 | 50.3 (15.8) |
P value = 2.98e-08 (Fisher's exact test), Q value = 4.1e-07
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
17P LOSS MUTATED | 64 | 14 |
17P LOSS WILD-TYPE | 509 | 498 |
P value = 0.0027 (Wilcoxon-test), Q value = 0.01
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
17P LOSS MUTATED | 56 | 74.8 (18.9) |
17P LOSS WILD-TYPE | 676 | 81.6 (14.9) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
17P LOSS MUTATED | 7 | 5 | 2 | 5 | 1 | 58 |
17P LOSS WILD-TYPE | 187 | 25 | 127 | 184 | 17 | 467 |
P value = 1.11e-05 (logrank test), Q value = 7.6e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
17Q LOSS MUTATED | 51 | 38 | 0.1 - 92.7 (11.7) |
17Q LOSS WILD-TYPE | 1027 | 560 | 0.0 - 211.2 (16.3) |
P value = 0.000383 (Wilcoxon-test), Q value = 0.0018
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
17Q LOSS MUTATED | 51 | 58.3 (13.5) |
17Q LOSS WILD-TYPE | 1033 | 50.4 (15.8) |
P value = 9.74e-06 (Fisher's exact test), Q value = 6.9e-05
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
17Q LOSS MUTATED | 42 | 9 |
17Q LOSS WILD-TYPE | 531 | 503 |
P value = 0.0277 (Wilcoxon-test), Q value = 0.077
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
17Q LOSS MUTATED | 36 | 74.2 (21.6) |
17Q LOSS WILD-TYPE | 696 | 81.4 (14.8) |
P value = 0.00061 (Fisher's exact test), Q value = 0.0028
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
17Q LOSS MUTATED | 4 | 3 | 1 | 4 | 1 | 38 |
17Q LOSS WILD-TYPE | 190 | 27 | 128 | 185 | 17 | 487 |
P value = 0.101 (Wilcoxon-test), Q value = 0.21
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
18P LOSS MUTATED | 137 | 52.8 (15.8) |
18P LOSS WILD-TYPE | 947 | 50.5 (15.8) |
P value = 0.102 (Wilcoxon-test), Q value = 0.22
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
19P LOSS MUTATED | 44 | 85.0 (12.8) |
19P LOSS WILD-TYPE | 688 | 80.8 (15.4) |
P value = 0 (logrank test), Q value = 0
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
19Q LOSS MUTATED | 241 | 70 | 0.1 - 182.3 (22.3) |
19Q LOSS WILD-TYPE | 837 | 528 | 0.0 - 211.2 (14.9) |
P value = 1.65e-08 (Wilcoxon-test), Q value = 2.3e-07
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
19Q LOSS MUTATED | 243 | 45.9 (13.5) |
19Q LOSS WILD-TYPE | 841 | 52.2 (16.1) |
P value = 2.55e-46 (Fisher's exact test), Q value = 9.9e-45
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
19Q LOSS MUTATED | 34 | 210 |
19Q LOSS WILD-TYPE | 539 | 302 |
P value = 1.16e-13 (Fisher's exact test), Q value = 2.6e-12
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
19Q LOSS MUTATED | 102 | 126 |
19Q LOSS WILD-TYPE | 156 | 644 |
P value = 3.01e-06 (Wilcoxon-test), Q value = 3.2e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
19Q LOSS MUTATED | 158 | 85.6 (13.2) |
19Q LOSS WILD-TYPE | 574 | 79.8 (15.6) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
19Q LOSS MUTATED | 23 | 2 | 44 | 143 | 2 | 30 |
19Q LOSS WILD-TYPE | 171 | 28 | 85 | 46 | 16 | 495 |
P value = 0.00952 (Fisher's exact test), Q value = 0.031
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
19Q LOSS MUTATED | 18 | 208 |
19Q LOSS WILD-TYPE | 26 | 713 |
P value = 0.0456 (Fisher's exact test), Q value = 0.12
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
20P LOSS MUTATED | 19 | 7 |
20P LOSS WILD-TYPE | 554 | 505 |
P value = 0.109 (Fisher's exact test), Q value = 0.23
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
20P LOSS MUTATED | 15 | 11 |
20P LOSS WILD-TYPE | 438 | 621 |
P value = 0.0664 (Fisher's exact test), Q value = 0.16
nPatients | AMERICAN INDIAN OR ALASKA NATIVE | ASIAN | BLACK OR AFRICAN AMERICAN | WHITE |
---|---|---|---|---|
ALL | 1 | 21 | 71 | 959 |
20P LOSS MUTATED | 0 | 2 | 3 | 21 |
20P LOSS WILD-TYPE | 1 | 19 | 68 | 938 |
P value = 0.0132 (Fisher's exact test), Q value = 0.041
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
20Q LOSS MUTATED | 17 | 4 |
20Q LOSS WILD-TYPE | 556 | 508 |
P value = 0.0734 (Fisher's exact test), Q value = 0.17
nPatients | FEMALE | MALE |
---|---|---|
ALL | 453 | 632 |
20Q LOSS MUTATED | 13 | 8 |
20Q LOSS WILD-TYPE | 440 | 624 |
P value = 0.076 (Fisher's exact test), Q value = 0.17
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
20Q LOSS MUTATED | 2 | 1 | 2 | 0 | 0 | 16 |
20Q LOSS WILD-TYPE | 192 | 29 | 127 | 189 | 18 | 509 |
P value = 0.0358 (Fisher's exact test), Q value = 0.096
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
21Q LOSS MUTATED | 23 | 2 | 7 | 6 | 1 | 39 |
21Q LOSS WILD-TYPE | 171 | 28 | 122 | 183 | 17 | 486 |
P value = 2.15e-14 (logrank test), Q value = 5e-13
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
22Q LOSS MUTATED | 240 | 182 | 0.1 - 156.2 (13.9) |
22Q LOSS WILD-TYPE | 838 | 416 | 0.0 - 211.2 (16.7) |
P value = 2.04e-13 (Wilcoxon-test), Q value = 4.4e-12
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 1084 | 50.8 (15.8) |
22Q LOSS MUTATED | 240 | 57.2 (14.8) |
22Q LOSS WILD-TYPE | 844 | 49.0 (15.6) |
P value = 4.56e-17 (Fisher's exact test), Q value = 1.2e-15
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
22Q LOSS MUTATED | 183 | 57 |
22Q LOSS WILD-TYPE | 390 | 455 |
P value = 0.00135 (Fisher's exact test), Q value = 0.0056
nPatients | NO | YES |
---|---|---|
ALL | 258 | 770 |
22Q LOSS MUTATED | 39 | 189 |
22Q LOSS WILD-TYPE | 219 | 581 |
P value = 0.00647 (Wilcoxon-test), Q value = 0.022
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
22Q LOSS MUTATED | 169 | 79.0 (15.0) |
22Q LOSS WILD-TYPE | 563 | 81.7 (15.3) |
P value = 1e-05 (Fisher's exact test), Q value = 6.9e-05
nPatients | ASTROCYTOMA | GLIOBLASTOMA MULTIFORME (GBM) | OLIGOASTROCYTOMA | OLIGODENDROGLIOMA | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|---|---|---|---|
ALL | 194 | 30 | 129 | 189 | 18 | 525 |
22Q LOSS MUTATED | 29 | 9 | 11 | 17 | 6 | 168 |
22Q LOSS WILD-TYPE | 165 | 21 | 118 | 172 | 12 | 357 |
P value = 0.119 (Fisher's exact test), Q value = 0.24
nPatients | HISPANIC OR LATINO | NOT HISPANIC OR LATINO |
---|---|---|
ALL | 44 | 921 |
XP LOSS MUTATED | 13 | 178 |
XP LOSS WILD-TYPE | 31 | 743 |
P value = 0.0895 (logrank test), Q value = 0.19
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 1078 | 598 | 0.0 - 211.2 (16.0) |
XQ LOSS MUTATED | 172 | 101 | 0.1 - 134.3 (15.1) |
XQ LOSS WILD-TYPE | 906 | 497 | 0.0 - 211.2 (16.2) |
P value = 0.047 (Fisher's exact test), Q value = 0.12
nPatients | BRAIN | CENTRAL NERVOUS SYSTEM |
---|---|---|
ALL | 573 | 512 |
XQ LOSS MUTATED | 104 | 70 |
XQ LOSS WILD-TYPE | 469 | 442 |
P value = 0.0881 (Wilcoxon-test), Q value = 0.19
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 732 | 81.1 (15.3) |
XQ LOSS MUTATED | 123 | 79.0 (15.9) |
XQ LOSS WILD-TYPE | 609 | 81.5 (15.1) |
-
Copy number data file = broad_values_by_arm.txt from GISTIC pipeline
-
Processed Copy number data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/GDAC_Correlate_Genomic_Events_Preprocess/GBMLGG-TP/22534382/transformed.cor.cli.txt
-
Clinical data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/Append_Data/GBMLGG-TP/22506567/GBMLGG-TP.merged_data.txt
-
Number of patients = 1085
-
Number of significantly arm-level cnvs = 82
-
Number of selected clinical features = 9
-
Exclude regions that fewer than K tumors have mutations, K = 3
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.